



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 1/22, 14/00, 17/00, C12N 15/09, C12Q 1/00	A1	(11) International Publication Number: WO 98/57978 (43) International Publication Date: 23 December 1998 (23.12.98)
(21) International Application Number: PCT/US98/12846 (22) International Filing Date: 19 June 1998 (19.06.98) (30) Priority Data: 60/050,171 19 June 1997 (19.06.97) US (71) Applicant (for all designated States except US): UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY [US/US]; 45 Knightsbridge Road, P.O. Box 8810, Piscataway, NJ 08855 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): MADURA, Kiran [US/US]; 16 Timberline Drive, Bridgewater, NJ 08807 (US). (74) Agents: RIGAUT, Kathleen, D. et al.; Dann Dofman Herrell and Skillman, Suite 720, 1601 Market Street, Philadelphia, PA 19103 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: METHODS AND COMPOSITIONS FOR RAPID PURIFICATION OF PROTEASOMES AND METHODS OF USE OF COMPONENTS THEREOF		
(57) Abstract Disclosed are methods for rapidly and efficiently purifying proteasomes using fusion proteins having homology to ubiquitin. Also disclosed are methods for assessing aberrant cell growth rates utilizing fusion proteins having homology to ubiquitin and a signal producing moiety.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**METHODS AND COMPOSITIONS FOR RAPID PURIFICATION OF
PROTEASOMES AND
METHODS OF USE OF COMPONENTS THEREOF**

This application claims priority under 35 U.S.C. §119(e) from U.S. Provisional Application, Serial Number 60/050,171 filed June 19, 1997, the disclosure of which is incorporated by reference herein.

Pursuant to 35 U.S.C. §202(c) it is acknowledged that the U.S. Government has certain rights in the invention described herein, which was made in part with funds from the the National Institutes of Health (GM-52058).

FIELD OF THE INVENTION

This invention relates to the field of proteolytic degradation of cellular proteins. More specifically, rapid and efficient methods for proteasome purification from various cell types are disclosed. Also provided are novel methods for use of the proteasome components so purified.

BACKGROUND OF THE INVENTION

Several publications are referenced in this application by author name and year of publication in parentheses in order to more fully describe the state of the art to which this invention pertains. Full citations for these references are found at the end of the specification. The disclosure of each of these publications is incorporated by reference herein.

The degradation of cellular proteins is necessary for the biological well-being of all organisms. Regulators of cell growth and development, and components of the immune and cellular defense mechanisms are regulated by proteolysis. Membrane receptors and transcription factors activated by cytokines, such as

interleukins and interferons, are regulated by protein degradation.

The major pathway of intracellular proteolysis involves the ubiquitin/proteasome system. Ubiquitin, a
5 76 amino acid polypeptide, is the most highly conserved protein in eukaryotic evolution. There are only 3 amino acid differences between yeast and human ubiquitins. Extensive studies during the past decade have shown that the covalent attachment of ubiquitin to cellular
10 proteins marks them for destruction. Substrates that are linked to ubiquitin are degraded by a multicatalytic protease called the proteasome. During the past few years many targets of the ubiquitin/proteasome system have been discovered and remarkably they include a broad
15 range of regulators of cell growth. Some of the proteins destroyed by the ubiquitin/proteasome system include cyclins, cyclin-dependent kinases (CDK's), NF κ B, I κ B α , cystic fibrosis transduction receptor, p53, ornithine decarboxylase (ODC), 7-membrane spanning
20 receptors, Cdc25 (phosphotyrosine phosphatase), Rb, G α , c-Jun and c-Fos.

The ubiquitin/proteasome pathway is also essential for the stress-response and for the generation of antigenic peptides in MHC Class I molecules. It is
25 clear that defects in the functioning of the ubiquitin/proteasome system can have severe consequences on biological homeostasis. Indeed, mutations that affect the degradation of many of the proteins listed above have been associated with tumorigenesis.

30 The 26S-proteasome comprises two distinct sub-complexes. The core complex has a sedimentation velocity of 20S and contains a variety of degradative activities. The 20S core is highly conserved across evolutionary distance and consists of a barrel of 4
35 rings. Each ring contains 7 subunits of either α class or β class. The rings are oriented so that two α -subunit-containing rings are on the outside, while two

β -subunit containing rings are juxtaposed on the inside. Thus, the 20S core is identical at its two ends. The x-ray structure of the archaeobacterial proteasome has recently been resolved and was shown to contain a narrow pore in each α ring, and a large central cavity formed by the β rings. Accordingly, the central cavity is not exposed to the cellular environment, thereby preventing non-specific degradation of cellular proteins. Proteins targeted for degradation are first threaded through the narrow pores in the α rings before they gain access to the central catalytic cavity.

The second sub-complex, referred to as the 19S-regulatory complex, binds to the ends of the 20S core and regulates access of cellular proteins to the catalytic cavity. The 19S complex, together with the 20S core make up the 26S-proteasome. The 19S complex has at least 6 distinct ATPase subunits which are thought to promote unfolding of proteolytic substrates so that they can be channeled through the narrow pores of the 20S core. The 19S complex contains as many as 20 subunits, which include a multiubiquitin-chain binding protein, isopeptidases and at least 6 ATPases. To date, many of these additional subunits remain uncharacterized.

The *Rad23* gene of *S. cerevisiae* is necessary for efficient nucleotide excision repair of damaged DNA. *In vitro* studies indicate that this factor may play a role in assisting the assembly of the repair complex at the site of damage. Accordingly, interactions between *Rad23p* and other repair proteins including *Rad4p*, *Rad14p*, and subunits of TFIIH have been proposed. Thus far, however, the exact biochemical function of *Rad23p* in DNA repair has remained unclear.

Rad23p has an NH_2 -terminal domain with striking homology to ubiquitin (22% identity, 43% homology). Watkins et al. have shown that this ubiquitin-like domain is required for repair activity of the protein

and that the domain can be replaced by the sequence of wild-type ubiquitin. In addition, a family of proteins with similar ubiquitin-like domains have been discovered. Unfortunately, these family members have diverse species of origin and apparently disparate functions and thus have provided no clue as the exact role of this domain.

As noted above, impaired activity of the proteasome is implicated in many diseases in humans. This observation has stimulated considerable research activity in the identification of novel therapeutic agents for inhibiting and/or stimulating the activity of the proteasome. These studies have been hindered by the inefficient, time-consuming, biochemical protocols available for the purification of proteasomes. The present invention describes a rapid and efficient proteasome purification method and provides novel methods of use of various proteasome subunits so purified.

SUMMARY OF THE INVENTION

The present invention provides compositions and a rapid and efficient method for the purification of proteasome complexes from a variety of cell types. In accordance with the present invention, it has been discovered that the ubiquitin-like N-terminal domain of a yeast protein, Rad23, has high affinity for the proteasome. Accordingly, this domain or homologues thereof may be immobilized to a suitable solid support and used to isolate the proteasome from cell lysates. Following removal of non-specifically bound proteins, the proteasomes are eluted. This method will facilitate the molecular characterization of the as yet unidentified subunits of the proteasome. Ubiquitin-like domains (UbL) in cellular proteins vary slightly between species. In one embodiment of the invention, UbL-domains from a given species will be used for proteasome

purification from cell lysates derived from cells of that species.

Another aspect of the invention is a kit of materials useful in performing the proteasome purification method of the invention. A kit according to this aspect of the invention comprises a solid support to which a UbL of interest has been affixed as well as suitable buffers for eluting proteasome preparations.

In a further embodiment of the invention, it has been discovered that this same N-terminal ubiquitin like domain of Rad23, UbL^{R23}, functions as a degradation signal in actively growing cells. Fusion proteins comprising this domain are provided herein. Reporter proteins attached to the UbL domain (UbL^{R23}-reporter) are rapidly degraded in logarithmically growing cells. Since a primary feature of malignant cells is the aberrant rate of cell growth, the UbL^{R23}-reporter provides a powerful way to assess the proliferative potential of tumor cells. In yet another embodiment of the invention, the efficacy of anti-cancer drugs can be assessed by determining the stability of the UbL^{R23}-reporter fusion proteins.

In a further aspect of the invention, compositions and methods are provided for enhancing the thermostability of fusion proteins containing the UbL domain. Such fusion proteins may be used to advantage in chemical reactions requiring thermostable reagents, such as the polymerase chain reaction (PCR). In this embodiment of the invention, DNA constructs are generated wherein a DNA sequence encoding a UbL-domain is operably linked to a DNA sequence encoding the protein to be thermostabilized using standard molecular biological techniques. Following expression of the DNA construct in a suitable host cell, the thermostable fusion protein is purified and utilized in biochemical assays requiring high temperatures.

In summary, the methods and kits of the invention are particularly useful for the assessing proteolytic degradation of cellular components via the proteasome. The DNA constructs of the invention encoding fusion proteins comprising UbL domains are useful for assessing the proliferative potential of malignant cells. UbL domains may also be utilized to enhance the thermostability of fusion proteins.

10 BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1E are an autoradiograph and western blots of cell extracts showing that Rad4-HA interacts with Rad23 and that Rad23 interacts with the 26S proteasome. Rad4 plays a role in DNA repair and stably interacts with Rad23. Figure 1A depicts the positions of [³⁵S] GST fusion proteins and [³⁵S] Rad-HA. Yeast strains simultaneously expressing the Rad4-HA and each of the GST-fusion proteins were metabolically labeled with ³⁵S-methionine for 10 minutes. Extracts were prepared and adsorbed to glutathione-Sepharose. Beads were washed extensively and bound proteins resolved by SDS-PAGE and detected by fluorography. Figures 1A, 1B and 1C, Lane 1, GST; lane 2; GST-Rad23; lane 3 GST^{ΔUbL}Rad23 and lane 4, GST-UbL^{R23}. Rad4-HA is detected in lanes 2 and 3 indicating that it interacts with C-terminal sequences in Rad23. Non-specific interactions of other cellular proteins with GST-UbL^{R23} are indicated by asterisks. Figure 1B is an immunoblot showing that Cim5 and Cim3 interact with GST-Rad23 and GST-UbL^{R23}. Figure 1C shows that the complex that interacts with GST-Rad23 and GST-UbL^{R23} contains the 20S subunit Pup1-HA. The additional band (asterisk) may represent a precursor form of Pup1-HA. Figure 1D is a blot showing that native Rad232 can be precipitated on FLAG-agarose beads in extracts derived from a yeast strain expressing Pre1-FLAG, an epitope tagged derivative of a 20S β-subunit. Figures 1D and 1E, lane 1, extract from Pre1-

flag cells; lane 2 extracts from negative control
extract lacking Pre-1-FLAG. Figure 1E is a blot showing
that extracts containing FLAG-Rad23 can specifically
precipitate Cim3 and Cim5 on FLAG-agarose beads. These
5 subunits were not recovered from extracts containing a
control vector lacking FLAG-Rad23 (lane 2).

Figure 2 is a series of graphs depicting the
proteolytic activity associated with UbL^{R23}. Flag-Rad23
10 was immunopurified and incubated with peptide
substrates. A control reaction with a strain expressing
an unrelated protein is also shown (Negative). The
relative levels of chymotrypsin, trypsin and PGPH-like
activities, and the effect of proteasome inhibitors
15 MG132 and lactacystin are shown. A (-) symbol indicates
the absence of the inhibitor. The values represent the
average of three measurements.

Figure 3 is fractionation data showing that Gst-
20 R23, Rad4-HA and Cim5 are components of a high molecular
weight complex. Figure 3A is a Coomassie stained gel
showing Mono-S fractions isolated following incubation
with glutathione-sepharose. Bound proteins were
separated by SDS-PAGE. Figures 3A, 3B, and 3C show
25 western blots treated sequentially with antibodies
against HA (Fig.3A), Cim5 (Fig. 3B) and Rad23 (Fig. 3C).
Figure 3D is a graph showing the ATPase activity
corresponding to the Mono-S fractions isolated.

30 Figure 4 is a blot showing that human HHR23-B
interacts with Mss1. The ubiquitin-like domain of
HHR23-B was linked to Gst (Gst-Ub^{HRB}) and incubated with
Hela cell nuclear extracts. Mss1 was detected with Cim5
antibodies (lane 2). Cim5 interaction with Gst-R23 is
35 also shown (lane 3).

Figures 5A and 5B are data showing the genetic

interaction between *RAD23* and the N-end rule pathway. Figure 5A shows that toxicity in yeast is caused by overexpressing the N-end rule pathway (CSY13, top). This toxicity is suppressed by high levels of *RAD23* (CSY41, left), or in *rad23Δ* (CSY41, right). Isogenic yeast strains were grown in minimal medium containing galactose and lacking appropriate nutrients to maintain plasmids. Figure 5B is a graph showing that Rad23-ha can complement *rad23Δ*. Exponential-phase yeast cells (JD47-13C; *RAD23*, closed squares, CSY85; *rad23Δ*, closed circles, and CSY131; CSY85 expressing Rad23-ha, open circles) were exposed to 15, 45 and 90J/m² UV light (n=3).

Figure 6 is an autoradiograph showing the results of pulse-labeling experiments which indicate that Rad23-HA is not degraded by Ubc4 or the N-end rule system. Figure 6A shows that Rad23-HA is unstable in *ubc4Δ ubc5Δ* suggesting that these E2 proteins do not affect its stability. Rad23-ha is also unstable in N-end rule pathway mutants, *ubc2Δ*, Figure 6B and *ubr1Δ*, shown in Figure 6C. The stability of Rad23-HA was comparable to that observed in the parental strain (Fig. 7A).

Figures 7A-7D are gels showing the growth-stage specific degradation of Rad23-HA. Fig 7A: Rad23-HA stability was measured in logarithmic- and stationary-phases of growth. The numbers at the top indicate minutes in chase medium. Rad23-HA (arrow) and a sepharose-interacting yeast protein (*) are indicated in this and subsequent figures. Fig. 7B: Stationary-phase yeast cells were labeled for 20 minutes and extracts were prepared to monitor the abundance of ³⁵S-Rad23-HA. The numbers at the top refer to samples withdrawn during the labeling (in minutes), and those indicated as + refer to minutes in chase medium lacking ³⁵S-label. Total ³⁵S-protein was also resolved on a second gel to

follow the levels of other cellular proteins (data not shown). Fig. 7C: The stability of Rad23¹⁻³⁶⁹ is shown in logarithmic- and stationary-phase cells. This C-terminal truncated allele does not possess a HA epitope but displays growth-stage specific degradation similar to Rad23-HA (Fig. 6A above) and UbL^{R23}-LacZ (Fig. 9B). Fig. 7D shows the degradation of other substrates of the ubiquitin system are unaffected by growth conditions. (R-β-gal is a substrate of the N-end rule pathway while ubiquitin-proline-β-gal is a substrate for the ubiquitin-fusion degradation (UFD) pathway. Met-β-gal is not a substrate of either pathway and therefore is stable in both logarithmic and stationary phase cells.

Figures 8A-8C are gels showing that transient growth-arrest does not affect Rad23-HA stability. The growth of exponential stage cells was arrested and Rad23-HA stability was measured. Fig. 8A: RYB 262 contains a temperature-sensitive allele of RNA polymerase II. The growth of RY262 expressing Rad23-HA was arrested at 37°C and pulse-chase analysis was performed. Fig. 8B: Hydroxyurea was added to exponentially growing cells (JD47-13C) expressing Rad23-HA and incubated for 2 hours at 30°C. Pulse-chase analysis was carried out when approximately 75% of the cells had arrested growth. Fig. 8C: A *bar1-1* strain expressing Rad23-HA was exposed to 10 ng/ml α-factor, and pulse-chase analysis was performed when approximately 95% of the cells had arrested in G₁.

Figures 9A and 9B are gels showing that UbL^{R23} is a regulated and portable degradation signal. Fig. 9A: Δ^{UbL} Rad23-HA was expressed in JD47-13C and stability was compared to Rad23-HA in exponential phase. Fig. 9B: UbL^{R23} was linked to β-galactosidase and the stability of UbL^{R23}-LacZ was determined in JD47-13C. A cluster of protein bands corresponding to UbL^{R23}-LacZ was detected

in stationary-phase extracts and are indicated by the bracket. UbL^{R23}-LacZ was almost undetectable in exponential-stage cells.

5 Figures 10A-10E show that Ufd5 is required for the degradation of Rad23-HA. Rad23-HA was expressed in a set of strains bearing mutations in *ufd1-5*. In vivo stability was measured by pulse-chase methods and quantitated by PhosphorImager. Only *ufd5*Δ was found to
10 be important for Rad23-HA degradation. An antibody cross-reacting band (*) served as a useful internal control for loading.

 Figures 11A-11E are a series of gels showing that
15 Rad23-HA is degraded by the proteasome. The *in vivo* stability of Rad23-HA in proteasome and vacuolar mutant strains is shown. Fig. 11A, *pre1-1/pre2-2*; Fig. 11B, *Cim5*; Fig. 11C, *doa*Δ-1; Fig. 11D, *mcb1*Δ; Fig. 11E, *pep4*Δ*prb1*Δ. An arrow indicates the position of Rad23-HA. A protein of approximately 70 kD which binds
20 Sephacose non-specifically is indicated by the asterisks.

 Figures 12A and 12B are a sequence alignment and
25 graph showing that Rad23 interacts with a putative subunit of the 26S proteasome. Rad23p was linked to *lexA* and *Irt1* was isolated in a 2-hybrid experiment. Fig. 12A shows the amino acid sequence corresponding to the ATPase domain of *Irt1* is aligned with the sequence
30 of closely related homologs of 26S proteasome subunits. Fig. 12B is a graph showing that the interaction between Rad23 and *Irt1*, and 3 C-terminal truncated alleles of *Irt1*, as determined by measuring β-galactosidase activity in the 2-hybrid yeast strain harboring both
35 plasmids. The data are representative of 6 independent measurements and are indicated in Miller units.

Figures 13A and 13B are gels showing that UbL's from different sources interact with the proteasome. GST linked proteins were expressed in yeast and purified on glutathione-Sepharose. Proteins retained on the beads were resolved in SDS-polyacrylamide gels, transferred to nitrocellulose, and incubated with antisera specific to proteasome subunits Cim3 and Cim5. The blot was developed by enhanced chemiluminescence (Amersham).
5
Fig. 13A: Lane 1 contains a GST control, and lanes 2-6 contain GST linked to UbL^{R23}, Ub, UbL^{DSK}, UbL^{HRA} and UbL^{HRB}.
10
Yeast strains expressing the GST linked proteins as well as Pre1-Flag, Fig. 13B. The blot was developed with anti-Flag antiserum (Kodak). The position of molecular weight markers are indicated.

15

Figures 14A and 14B are a series of blots showing that UbL's interact with the 19S/PA700 complex. In Fig. 14A GST-UbL^{HRA} and GST-UbL^{HRB} were purified and incubated with Hela cell S100 extract. Lane 1 contains a GST negative control, while lanes 2 and 3 contain GST-UbL^{HRA} and -UbL^{HRB}. Lane 4 contains GST-UbL^{R23} interacting proteins. Hela S100 extracts were incubated with GST, GST-UbL^{HRA} and GST-UbL^{HRB} and bound proteins were separated by SDS-PAGE and the western blot incubated with Cim5-specific antibodies, which crossreacts with the human counterpart Mss1. In Figure 13B, a similar set of GST linked proteins were incubated with purified 19S/PA700 and the bound proteins separated by SDS-PAGE and visualized by staining with silver nitrate. The profile of subunits that comprise the 19S/PA700 particle is shown in lane 1. Molecular weight standards are indicated in lane 5. (Lanes 1-5 were from the same gel).

20

25

30

35

Figure 15 is a gel showing that UbL^{R23} can target heterologous proteins to the proteasome. UbL^{R23} was linked to β -galactosidase and Ura3-HA and transformed

into yeast cells expressing GST-Cim5. Lane 1 contains affinity purified GST-Cim5. UbL^{R23}-βgal was immunopurified with anti-βgalactosidase antibodies and GST-Cim5 was co-purified (lane 2). An extract
5 containing only GST-Cim5 was treated with anti-βgalactosidase antibodies (lane 3). UbL^{R23}-Ura3-HA was precipitated with anti-HA antibodies and GST-Cim5 was co-purified (lane 4). An extract containing only GST-Cim5 was incubated with anti-HA antibodies and resolved
10 as a negative control (lane 5). The blot was developed with anti-GST antibodies. (H and L indicate the positions of immunoglobulin heavy- and light-chains from the HA immunoprecipitation).

15 Figures 16A and 16B are a pair of gels illustrating that UbL^{R23} interferes with the degradation of specific substrates. Yeast cells expressing a test protein Met-βgal, or substrates of the N-end rule (Arg-βgal and Leu-βgal) and UFD pathway (Ub-Pro-βgal) were transformed
20 with plasmids expressing GST or GST-UbL^{R23}. The stability of the proteins was determined by ³⁵S-pulse-chase methods. Samples were analyzed after 0, 10 and 60 min in Chase medium containing cycloheximide. The precipitated proteins were separated by SDS-PAGE and the
25 fluorograms exposed to X-ray film. This figure reproduces a dark exposure of the gel to reveal high molecular-weight derivatives of Leu-βgal and Ub-Pro-βgal (indicated as (Ub)_n) in cells expressing GST- UbL^{R23}.

30 Figure 17 is a graph showing the CD spectra of Rad23. The data show the spectra of a typical globular protein. The CD spectra of the protein is not altered by heating (not shown).

35 Figure 18 is a graph showing the melt profile of Rad23 at 222 nm frequency. It is significant to note that there is no temperature dependent unfolding of the

protein.

DETAILED DESCRIPTION OF THE INVENTION

5 The proteasome is an essential component of the
ATP-dependent proteolytic pathway in eukaryotic cells
and is responsible for the degradation of most cellular
proteins. The 20S (700 kDa) proteasome contains
multiple peptidase activities that function through a
new type of proteolytic mechanism involving a threonine
10 active site. The 26S (2000 kDa) complex, which degrades
ubiquitinated proteins, contains, in addition to the 20S
proteasome, a 19S regulatory complex composed of
multiple ATPases and components necessary for binding
protein substrates. The proteasome has been highly
15 conserved during eukaryotic evolution, and simpler forms
are found in archaebacteria and eubacteria.

The post-translational attachment of ubiquitin (Ub)
to cellular proteins is implicated in a broad range of
biological activities primarily involving protein
20 degradation (Hershko 1991). Ubiquitin is mobilized
through several *trans*-thiolation steps which precede its
isopeptide linkage to cellular substrates. Ubiquitin is
activated by adenylation of its C-terminal glycine
residue by the ubiquitin activating enzyme, E1 (Hershko
25 1991). Activated Ub is transferred from E1 to a family
of ubiquitin-conjugating enzymes (E2's or Ubc's) which
play significant roles in substrate selection. Emerging
evidence suggests that the transfer of Ub to a cellular
substrate may require an additional factor termed E3/Ub-
30 protein ligase (Hershko 1991; Scheffner et al. 1995), or
Ubr1/*n*-recognin (Varshavsky 1992). A well studied
substrate targeting mechanism of the ubiquitin system is
the N-end rule pathway (Varshavsky 1992), whose
overexpression inhibits the growth of haploid yeast
35 cells (Madura and Varshavsky, 1994). *RAD23*, a subunit
of the nucleotide excision repair complex was isolated
in a search for suppressors of this growth defect. The

present invention describes the biochemical analysis of alleles of Rad23 (Rad23-HA and Rad23-FLAG). It appears from these studies that Rad23 is involved in both DNA repair and the ubiquitin protein degradation pathway.

5 Previous studies have demonstrated that mutations in *RAD23* (*rad23Δ*) result in a defect in the repair of UV-irradiated DNA, which is manifested by an intermediate sensitivity to DNA damage (Friedberg et al. 1995). The moderate sensitivity of *rad23* to UV light is
10 contrasted by the severe defects observed in other excision repair mutants such as *rad1*, *rad2* and *rad4* which are unable to incise damaged DNA (Wilcox and Prakash 1981). The removal of DNA lesions is markedly reduced in *rad23Δ* but not abolished, suggesting that
15 Rad23 plays an accessory role in nucleotide excision repair. *In vitro* studies showed that Rad23 forms a stable interaction with the excision repair protein Rad4 (Guzder et al. 1995b), although the biological significance of this association is unclear. Rad23 also
20 interacts with other effectors, including the DNA damage-recognition protein Rad14 and the RNA PolIII-specific transcription factor TFIIH (Guzder et al. 1995a). A previously unknown function for Rad23 in spindle-pole body (SPB) duplication was recently
25 described (Biggins et al. 1996). These results indicate that Rad23 can participate in multiple regulatory pathways.

 It has been discovered that the Rad23 N-terminal domain (UbL^{R23}) has a strong affinity for the 26S-
30 proteasome and can be used to advantage to purify this proteolytic complex in a single step. Immobilizing this domain to a solid support, followed by exposure to cellular lysates results in the retention of the proteasome on the support. The proteasome can then be
35 released from the support following the prior elution of all other non-specifically adsorbed proteins. A family of proteins having Ub-like domains have been observed in

a variety of other species from yeast to humans (Toniolo et al. 1988; Wiborg et al., 1985). Ubiquitin-like domains in yeast Rad23 and Dsk2, as well as human HHR23A and HHR23B, are proteasome-interacting sequences. The attachment of UbL^{R23} to a reporter protein also targeted it to the proteasome, demonstrating that this is an autonomous function of a UbL. The ubiquitin-like domain of Rad23 (UbL^{R23}) interacts with a complex that contains subunits of the 26S proteasome and displays ATPase and protease activities expected for this proteolytic system. In agreement with this finding, proteasome-specific inhibitors caused marked reduction in the proteolytic activity associated with UbL^{R23}. The ubiquitin-like domain of Dsk2 (UbL^{DSK}) binds the proteasome preferentially in actively growing cells. Overexpression of UbL^{R23} inhibits the degradation of specific substrates of the ubiquitin pathway perhaps by saturating the proteasome targeting pathway. These results suggest that the physiological roles mediated by proteins containing ubiquitin-like motifs converge at the level of the proteasome, and may involve distinct proteasome subunits. The use of these ubiquitin-like homolog sequences for the purification of proteasomes from corresponding cell types, (e.g., human UbL-domains to purify human proteasomes or yeast UbL-domains to purify yeast proteasomes) is contemplated to be within the scope of the invention.

Kits are provided for purifying proteasomes from a variety of cell types. Such kits would include predetermined UbL domains fused to a solid support. The kit of the invention may also conveniently include a device for purifying biological samples, together with various solutions which may be used in performing the purification procedure, such as buffer(s), saline, diluent, controls and the like.

In accordance with another aspect of the present invention, it has been discovered that the half-life of

Rad23-HA is tightly regulated, ranging from approximately 1 minute in actively growing cells to greater than 1 hour in stationary-phase. In contrast to the instability of the epitope-tagged Rad23-HA allele,
5 it was previously reported that native Rad23 is stable (Watkins et al. 1993). Data presented herein reveal that Rad23 is degraded during the G1/S phase of the cell cycle. Specifically, data are described which indicate that the ubiquitin-like domain of Rad23 (UbL^{R23}) is an
10 autonomous and regulated degradation signal. Two additional lines of evidence suggest a direct interaction with the proteolytic apparatus: 1) Rad23 interacts with Irt1, a protein that has strong similarity to ATPase subunits of the 26S proteasome, and
15 2) immunopurified 26S proteasome contains native Rad23. Although the fraction of Rad23 that is associated with the proteasome is not known, the findings presented herein strongly implicate a proteolytic function for Rad23.

20 Malignant cells display aberrant growth properties and do not respond to normal regulatory signals. Malignancy therefore arises because aberrant cells continue to grow in conditions when normal cells remain quiescent. Detection and treatment of proliferative
25 disorders must begin with the clear identification of cells that manifest aberrant growth rates. Although malignant cells are often morphologically distinguishable from their wildtype counterparts, a quantitative measurement of the growth properties of
30 cells is lacking.

In another embodiment of the present invention, methods are provided which employ UbL^{R23}-LacZ fusion protein(s) to assess cell growth rates in evolutionarily
35 divergent organisms from yeast to humans. UbL-fusion proteins in rapidly dividing cells are degraded rapidly whereas those in quiescent cells remain stable. Proliferative rates are then determined based upon the

half life of the fusion protein within the cell. Additionally, UbL^{R23} can be linked to selectable markers, as well as genes that confer drug resistance. In these types of assays, cells that stabilize a fusion protein produced from a DNA construct composed of UbL^{R23} coding sequence linked to a drug resistance gene would survive in the presence of the drug. It is expected that proliferating cells will actively degrade the fusion protein and succumb to the presence of the drug. In a quantitative assay such as this, dose titrations are employed to define the conditions that promote the killing of malignant cells without harming normal cells.

The ubiquitin-like domain UbL^{R23} has been operably linked to the reporter protein β -galactosidase (UbL^{R23}-LacZ) to demonstrate the feasibility of this concept. In earlier studies performed in this laboratory, growth dependent degradation of native Rad23 was observed. These data suggested that UbL^{R23} was an important component of the degradation signal. As proposed, UbL^{R23}-LacZ fusion proteins proved to be exceedingly unstable in actively growing cells but entirely stable in quiescent cells, mimicking the degradation profile of Rad23 protein.

To further assess the suitability of using UbL^{R23}-LacZ fusion proteins to assess growth potential, this fusion protein was produced in cells expressing various Ras mutants. Ras proteins are highly conserved small GTP-binding regulators that control growth, differentiation and a variety of other cellular functions. Oncogenic alleles of Ras are hyperactive and do not arrest growth properly, while null mutants of Ras arrest growth prematurely. The data revealed that the level of UbL^{R23}-LacZ was almost undetectable in a strain expressing the oncogenic Ras mutant, while elevated levels of UbL^{R23}-LacZ were detected in cells lacking Ras. These findings corroborate the proposal that UbL^{R23}-LacZ is a suitable reporter protein to assess the

proliferative potential of cells.

The strategy described above enables the identification of genetic mutants that promote or attenuate the degradation of the UbL^{R23}-linked chimeras. It is anticipated that such mutants would either promote or inhibit proliferation. This method also provides a way to screen for compounds that promote quiescence. For instance, if UbL^{R23} is linked to a gene that confers drug resistance, the expression of drug resistance should be confined to quiescent cells, or cells whose growth has been artificially arrested.

In yet another aspect of the present invention, it has been discovered that the UbL^{R23} domain confers thermostability on Rad23 and on fusion proteins to which this domain has been operably-linked. Thus the UbL domain is a cis-acting temperature stabilizer. This domain can be used to advantage to create fusion proteins with enhanced thermostability.

PCR assays utilize the Taq polymerase enzyme which functions at the higher temperatures required for PCR yet also generates errors in the amplified sequences as the enzyme exhibits reduced fidelity in DNA copying. In one embodiment of the invention, the UbL domain may be fused to a polymerase enzyme which has a reduced error rate. Such fusion proteins can be used in PCR assays to increase the fidelity of DNA amplification.

The definitions set forth below are provided to facilitate understanding of the subject matter of the present invention:

The term proteasome refers to a 26S multicatalytic protease.

The phrase N-end rule pathway relates the *in vivo* half-life of a protein to the identity of its amino-terminal residue. Overexpression of targeting components of the N-end rule pathway in *S. cerevisiae* inhibits the growth of yeast cells.

The term promoter region refers to the 5'

regulatory regions of a gene. In the present invention, the use of both strong constitutive gene promoters and inducible gene promoters is contemplated.

5 The term operably linked means that the regulatory sequences necessary for expression of the coding sequence are placed in the DNA molecule in the appropriate positions relative to the coding sequence so as to effect expression of the coding sequence. This same definition is sometimes applied to the arrangement
10 of transcription units and other transcription control elements (e.g. enhancers) in an expression vector. The term may also be used to describe the fusion of a nucleic acid sequence encoding a UbL domain of the invention to a second nucleic acid sequence encoding a
15 protein of interest. Expression of the fused nucleic acid sequences results in the production of a fusion protein.

The term fusion protein refers to a chimeric protein molecule comprising two or more domains from
20 different sources.

The term DNA construct refers to genetic sequence used to transform cells. These constructs may be administered to cells in a viral or plasmid vector.

The term reporter gene refers to a gene whose
25 expression may be assayed; such genes include, without limitation, *lacZ*, amino acid biosynthetic genes, e.g., the yeast *LEU2*, *HIS3*, *LYS2*, or *URA3* genes, nucleic acid biosynthetic genes, the mammalian chloramphenicol transacetylase (CAT) gene, the green fluorescent protein
30 (GFP) or any surface antigen gene for which specific antibodies are available.

The term selectable marker gene refers to a gene product that when expressed confers a selectable phenotype such as antibiotic resistance on a transformed
35 cell.

Methods of delivery of the DNA constructs of the invention to target cells include electroporation, CaPO_4

precipitation, lipid-based systems and microinjection. Standard methods for delivery of DNA and protocols for preparing the transforming DNA may be found in Current Protocols in Molecular Biology, eds. Frederick M. Ausubel et al., John Wiley & Sons, 1995.

The following specific examples are provided to illustrate various embodiments of the invention. They are not intended to limit the scope of the invention in any way.

EXAMPLE I

RAPID AND EFFICIENT PURIFICATION OF PROTEASOMES USING RAD23 AND COMPONENTS THEREOF

Rad23 has an unusual N-terminal domain that bears a striking resemblance to ubiquitin (Watkins et al., 1993). This domain, which has been designated UbL^{R23}, is important for DNA repair because its elimination causes sensitivity to UV light (Watkins et al., 1993). A role for Rad23 in the ubiquitin system was suggested by its suppression of N-end rule induced toxicity, which raised the possibility of a proteolytic function in DNA repair.

Rad23 and Rad4, as well as the human counterparts HHR23-B and XPC, form stable interactions. We therefore tested whether GST-Rad23 interacts with components of the DNA repair and proteolytic pathways. We linked Rad4 to the HA epitope (SEQ ID NO: 17: Try-Pro-Try-Asp-Val-Pro-Asp-Tyr-Ala (Rad4-HA) and found that it complemented *rad4Δ*. GST-Rad23 and Rad4-HA were expressed simultaneously in yeast cells and metabolically labeled with [³⁵S]-methionine. Radiolabeled extracts were applied to glutathione-Sepharose and bound proteins analyzed by SDS-PAGE and fluorography. Rad4-HA interacts with GST-R23. See Figure 1A, lane 2. The interaction of Rad4-HA with GST-Rad23 did not require UbL^{R23}, (Fig. 1A, lane 3) demonstrating that distinct regions of Rad23 interact with the proteolytic and DNA repair pathways. Identical samples were transferred to nitrocellulose and analysed by incubation with anti-HA

antibodies and, consistent with these findings, RAD4-HA was detected only in lanes 2 and 3. These findings are in agreement with a recent report showing that 21 C-terminal residues in Rad23 are important for interaction with Rad4.

To further explore the proteolytic function of Rad23 in DNA repair, Rad23 and two truncated mutants were operably linked to glutathione-S-transferase (GST-Rad23, GST-^{ΔUbl}Rad23, and GST-Ubl^{R23}), and immobilized on glutathione-Sepharose. Western blots containing the proteins released from GST and GST-Rad23 beads were incubated with antibodies against Cim3 (Sug1) and Cim5. Cim3 and Cim5 are ATPases of the regulatory (19S) subunit of the 26S proteasome. Both Cim3 (M_r 43K) and Cim5 (M_r 54K) were detected in the GST-Rad23 beads (Fig. 1B, lane 2) but not in the control GST beads (Fig. 1B, lane 1). GST-Ubl^{R23} alone could efficiently bind a complex containing Cim3 and Cim5 (Fig. 1B, lane 4) but, a mutant lacking Ubl^{R23} (GST-^{ΔUbl}Rad23) could not (Fig. 1B, lane 3). Two variants of Rad23, bearing small epitopes on either the N-terminus (FLAG-Rad23, Fig. 1e) or the C-terminus (Rad23-HA, data not shown) also interacted with the proteasome. Both Cim3 and Cim5 were detected in anti-FLAG immunoprecipitates prepared from yeast cells expressing FLAG-Rad23 (Fig. 1E). Because yeast cells expressing ^{ΔUbl}Rad23 fail to complement *rad23Δ*, these findings suggest that Rad23-proteasome interaction is important for DNA repair. These data also show that Ubl^{R23} represents a new proteasome interaction signal. A large family of proteins bearing ubiquitin-like extensions have been identified, and our results suggest that they too have proteolytic functions.

To determine whether the GST-Rad23 interacting complex included 20S catalytic subunits, extracts from cells expressing Pre1-FLAG (28K) or Pup1-HA (33K), both of which are epitope-tagged derivatives of 20S β-subunits were analyzed. Both Pup1-HA (Fig. 1C, lane 2)

and Pre1-Flag (data not shown) were detected in GST-Rad23 beads after incubation with FLAG or HA antibodies, confirming the presence of 20S catalytic subunits. GST-UbL^{R23} accumulated to higher levels than than GST-Rad23, and the recovery of Pup1-HA was proportionately higher (Fig. 1C, compare lanes 2 and 4). To confirm that the findings applied to native Rad23, Pre1-FLAG was immunoprecipitated on FLAG-agarose beads and interacting proteins were resolved on SDS-PAGE. Proteins were transferred to nitrocellulose and the blots were incubated with Rad23-specific antibodies. Native Rad23 was readily detectable in immunoprecipitates containing Pre1-FLAG but not from a control extract lacking this epitope-tagged proteasome subunit (Fig. 1D).

Approximately 5% of cellular Rad23 precipitated with Pre1-FLAG. This estimate is based on the amount of Rad23 that remained on the FLAG-agarose beads after 18 hours at 4°C. The *in vivo* interaction could be higher if the interaction with the proteasome is transient or regulated.

To examine if the Rad23 interacting complex had proteasome-specific activities we measured ATPase (Merrick, W.C., 1979), and protease activities (Heinemeyer et al., 1991). We found that high levels of ATPase activity were associated with FLAG-Rad23 (Kibel et al., 1995). Consistent with this finding, high proteolytic activity was detected against three different peptide substrates in FLAG-Rad23 immunoprecipitates. This activity was significantly reduced by the proteasome inhibitors MG132 and lactacystin (Coux et al., 1996). See Figure 2.

To characterize the interaction of Rad4 with Rad23, extracts were prepared from cells expressing both GST-Rad23 and Rad4-HA and proteins separated on Sephacryl S-200. GST-Rad23 was detected in the void volume coincident with dextran blue, and also in fractions corresponding to its predicted monomeric size

(approximately 80K). GST-Rad23, Cim5 and Rad4-HA could each detected in the high molecular weight fraction, suggesting that they are components of a single complex. See Figures 3A-C, lane 2.

5 To investigate this further, proteins in the Sephacryl S-200 void volume were chromatographed on Mono-Q. GST-Rad23, Rad4-HA, and Cim5 were detected in samples eluting at approximately 0.35M KCl. Significantly, these fractions were previously shown to
10 contain catalytically active proteasome (Rubin et al., 1996). Fractions that eluted between 325 and 375 mM KCl from the Mono-Q column were pooled and chromatographed on Mono-S. Cim5 and Rad4-HA again co-fractionated with
15 GST-Rad23 (Fig. 3A-3C, lanes 15-18) and a peak of ATPase activity copurified with the GST-Rad23 interacting complex. See Figure 3D.

As mentioned previously, two human homologues of Rad23, HHR23-A and HHR23-B contain N-terminal ubiquitin-like domains, suggesting that they act in a similar way
20 to the yeast protein, Rad23. Significantly HHR23-B forms a stable interaction with XPC, the human counterpart of Rad4. To explore the functional relatedness among this class of proteins, the ubiquitin-like domain of HHR23-B (UbL^{HRB}) was linked to GST. GST-UbL^{HRB}
25 was immobilized on glutathione sepharose and reacted with nuclear extracts prepared from Hela cells (a gift from D. Reinberg, RWJMS, New Jersey). Cim5 antibodies revealed an interaction between Gst-UbL^{HRB} and Mss1, the human equivalent of Cim5. See Figure 4, lane
30 2. GST-Rad23 interaction with Cim5 (lane 4) confirmed the specificity of the antibody reaction. The evolutionary conservation of yeast and human DNA repair and ubiquitin pathways strongly suggests that the
35 molecular interactions reported here are evidence of a novel mechanism for regulating DNA repair in yeast and humans. These findings also indicate that ubiquitin-like sequences represent a novel class of proteasome-

interacting domains, and their characterization may facilitate the molecular elucidation of the mechanistic action of proteins that bear this domain.

As exemplified herein, UbL-like domains can be used to efficiently purify the proteasome. This rapid purification method enables purification from a variety of cell types. The UbL-domains may be immobilized to a solid support such as an immunoaffinity column. Following immobilization, the column is exposed to cell lysates, non-specific proteins are eluted and the immobilized proteasome subsequently purified.

Exemplary UbL-domain containing sequences for use in the methods of the present invention are set forth below:

15

```

UB      MQ      IFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPP
DSK     MSLNIHIKSGQDKWEVNVAPESTVLQFKEAINKANGIPV
RAD     MVS LTF  KNFKKEKVP L D L E  PSNTILETKTKLAQSI SCEE
HRB     MQV     TLKTLQQQT F K I D I D P E E T V K A L K E K I E S E K G K  D A
HRA     MAVTITLKTLLQQQT F K I R M E P D E T V K V L K E K I E A E K G R  D A
212    AVHLTLKKIQAPKFSIEHDFSPSDTILQIKQHL      IS  EEKA
RUB1   MI      VKVKTLTGKEISVELKESDLVYHIKE      LL      EEKE
173    EEIAAF  RIFRKKSTSNLKS SHTT SNLVKKT MFKRDLLKQD

UB      D          QQR L I F A G K Q L E D G R T L S D Y N I Q K E S T  L H L V L R L R G G
DSK     AN          QR L I Y S G K I L K D D Q T V E S Y H I Q D G H S  V H L V K S Q P K P
RAD     S          Q I K L I Y S G K V L Q D S K T V S E C G L K D G D Q V V F M V  S Q K K S
HRB     F P V A G  Q K L I Y A G K I L N D D T A L K E Y K I D E K N F V V V M V T K P K A
HRA     F P V A G  Q K L I Y A G K I L S D D V P I R D Y R I D E K N F V V V M V T K T K A
212    S H I S   E I K L L L K G K V L H D N L F L S D L K V T P A N S T I T V M I K P N P T I S
RUB1   G I P P S Q Q R L I F Q G K H S D D K L T V T D A H L V E G M Q L K L V L T L R G G
173    P K R K L Q L Q Q R F A S P T D R L V S P C S L K L N E H K V K M F G K K K K V N P M
    
```

Sequences listed above:

20 SEQ ID NO: 1 Ub: ubiquitin
 SEQ ID NO: 2 DSK: yeast Dsk2
 SEQ ID NO: 3 RAD: yeast Rad23

SEQ ID NO: 4 HRB: human Rad23-B (HHR23-B)
 SEQ ID NO: 5 HRA: human Rad23-A (HHR23-A)
 SEQ ID NO: 6 212: yeast protein of unknown function that
 5 SEQ ID NO: 7 RUB1: yeast ubiquitin-like protein that is
 post-translationally conjugated to
 other proteins
 SEQ ID NO: 8 173: yeast protein of unknown function that
 10 contains an internal UbL

15 Additional ubiquitin-like domain sequences for use
 in the methods of the present invention are set forth
 below:

SEQ ID NO: 9 SUMO1
 MSDQEAKPSTEDLGDKKEGEYIKLKVIGQDSSEIHFVKVMTTHLKKLKESYQORQGVPMNSLRFLFE
 20 GQRIADNHTPKELGMEEEDVIEVYQEQTGGHSTV

SEQ ID NO: 10 SMT3B
 MADEKPKEGVKTENNDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQPI
 NETDTPAQLMEDEDTIDVFQQQTGGVY

25 SEQ ID NO: 11 SMT3A
 MSEEKPEGVKTENDHINLKVAGQDGSVVQFKIKRHTSLSKLMKAYCERQGLSMRQIRFRFDGQPIN
 ETDTPAQLRMEDEDTIDVFQQQTGGVPE

SEQ ID NO: 12 SMT3 yeast
 30 MSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLMEAFQKROGKEMDSLRLFLY
 DGIRIQADQTPEDLDMEDNDIIEAHREQIGGAT

35 SMT3: yeast ubiquitin-like protein that is
 post-translationally conjugated to other
 proteins like ubiquitin and RUB1.

SUMO: mammalian homolog of the yeast SMT3

Elongin: mammalian protein containing UbL that is not
 conjugated to other proteins

40 *parkin*: UbL-containing protein implicated in
 juvenile Parkinson's disease

EXAMPLE II

RAD23 AND ITS ROLE IN PROTEIN DEGRADATION

5

Nucleotide excision repair is enhanced by Rad23, a member of a class of proteins that bear unusual ubiquitin-like extensions at their N-termini. Specific modifications of Rad23 cause rapid degradation via the ubiquitin/proteasome system. Surprisingly, the short *in vivo* half-life of these variants does not affect the DNA damage response and can be reconciled with a growth-stage specific function for Rad23. The degradation signal in Rad23 resides in its N-terminal ubiquitin-like domain (UbL^{R23}), which confers instability when placed on a heterologous protein. Evidence for a proteolytic function for Rad23 is suggested by its interaction with Irt1p, a protein that bears a striking resemblance to members of the ATPase subunits of the 26S proteasome. Rad23 can be co-precipitated with immunopurified 26S proteasome, implicating a proteolytic function during DNA repair.

Materials and Methods for Example II

25 *Isolation of high-copy suppressors of N-end rule overexpression*

Yeast strain KMY950 was generated by transforming JD47-13C with a 2 μ m-based plasmid expressing *UBR1* and *UBC2* from the galactose-inducible *GAL1/10* promoter. The growth of KMY950 is severely impaired on galactose-containing medium due to overexpression of the N-end rule pathway (Madura and Varshavsky 1994). KMY950 was transformed (Gietz et al. 1992) with a plasmid library expressing yeast cDNAs from the *GAL1* promoter (Liu et al. 1992). Based on control plating experiments, we estimated that a total of approximately 10⁵ transformants were analyzed. Plasmid DNAs that enabled

KMY950 to grow on galactose-containing medium were identified and subjected to sequence analysis by the dideoxy chain-terminating method. One strong suppressor (plasmid pCEP10) encoded the complete open reading frame of the yeast *RAD23* gene.

Strains, media, growth conditions and genetic techniques

S. cerevisiae strains include JD47-13C (*MATa his3-Δ200 leu2-2, 112 ura3-52 trp1-Δ63 lys2-801*); CSY85 (*rad23Δ::URA3* in JD47-13C); CSY228 (5-FOA cured *ura⁻* derivative of CSY85); BR4 (*MATα pre1-1 pre2-2 ura3-Δ5 leu2-2, 112 his3-11, 15*); RY262 (*MATα his4-518 ura3-52 rpb1-1*); BJ5457 (*MATα ura3-52 trp1 lys2-801 leu2-Δ1 his3-Δ200 pep4::HIS3 prb1Δ1.6R can1*); Y791 (*MATa his3-Δ200 leu2-Δ1 ura3-2 cim5-1*); KMY334 (*MATa his7 cdc7-4 ura3 bar1-1*); CTY10-5d (*MATa ade2 gal4 gal80 his3-Δ200 leu2-3, 112 trp1-Δ901 URA3-lexop GAL1-LacZ*). The *ubc4Δ*, *ubc5Δ*, *ubc4Δ ubc5Δ* and the congenic wildtype strains have been described previously (Chen et al. 1993). A *rad4Δ::URA3* deletion was made in MKP°; (*MATα ade2 lys2 can1-100 his3-Δ200 ura3-52 trp1-Δ901 leu2-2, 112*). *E. coli* strain MC1066, bearing the *pyrF74:pn5* mutation was used to select plasmids expressing yeast *URA3*. Yeast growth media were prepared as described previously (Guthrie and Fink, 1991). The expression of genes linked to the *CUP1* promoter was induced by the addition of 0.1 mM CuSO_4 . For pulse-chase analysis exponential-phase cells were grown to a density at A_{600} of approximately 0.5 and stationary phase cultures were grown to $A_{600} > 2.5$. In experiments where we measured the stability of Rad23-ha in both conditions, stationary-phase cultures were collected (25 ml) by centrifugation, washed and resuspended in a small volume of sterile dH_2O . The cell suspension was inoculated into the used stationary-phase medium and fresh YPD medium, and incubated with vigorous aeration at 30°C for 4-5 hours to enable the YPD cultures to resume exponential growth.

After 4 hours at 30°C the density of the YPD culture increased by approximately 2-fold, indicating recovery from stationary phase.

5 *Plasmids, DNA manipulations and DNA sequencing*

Recombinant methods were performed by standard procedures (Ausubel, 1992). We amplified *RAD23* by polymerase chain reaction (PCR) using oligonucleotide primers (#42: 5'-GCGAATTCATGGTTAGCTTAACC-3' (SEQ ID NO: 13) and #41: 5'-GCGGTACCCGTCGGCATGATCGCTG-3') (SEQ ID NO: 14). The primers introduced an *EcoRI* site on the 5' end and a *KpnI* site on the 3' end of the DNA fragment. A 1.2 kb *EcoRI-KpnI* PCR DNA fragment was ligated to *EcoRI/KpnI*-digested pKM1362-2 (Madura and Varshavsky, 1994), yielding plasmid pCS8. In pCS8, Rad23p is linked to a C-terminal HA-epitope (Rad23-ha) and is expressed from the *CUP1* promoter. To construct *rad23Δ* a 4.8 kb *EcoRI* fragment containing a disrupted allele of *RAD23* was excised from pDG28 (Madura and Prakash, 1990) and used to replace the wild-type gene in JD47-13C by homologous recombination (Rothstein 1991). The resulting *rad23Δ::URA3* strain (CSY85) was plated on 5-FOA containing medium to isolate CSY228, a *ura*-derivative (Boeke et al. 1984). To make Rad23-ha lacking its N-terminal ubiquitin-like domain (pWP1), DNA sequence encoding codons 78 to 398 were amplified using oligonucleotide primers (88: 5' GCGAATTCATGACGAAGACCAAACTAACAGAA-3'; SEQ ID NO:15, and 41: SEQ ID NO: 14) and ligated to pKM1362-2, as described above. Similarly, DNA sequence corresponding to codons 1-77 (Ubl^{R23}) were amplified and ligated to LacZ in pKM1362-2 to yield Ubl^{R23}-LacZ. Oligonucleotide primers, specific to the coding sequence of β-galactosidase gene (beginning at codon # 8), were used to amplify LacZ.

Two-hybrid system screen and cloning of IRT1

RAD23 was isolated on a *Dra*I-*Eco*R1 DNA fragment, treated with DNA Pol1-Klenow, and ligated to similarly treated *Bam*H1 digested pBTM116 (Paetkau et al. 1994). The resulting plasmid DNA, encoding *lexA-Rad23*, was transformed into CTY10-5d. Yeast genomic DNA libraries were transformed into CTY10-5d expressing *lexA-Rad23p* and approximately 2.4×10^5 transformants were screened to identify blue colonies on indicator plates. Plasmid DNAs were purified from colonies that displayed an interaction (based on the color assay), and were subject to DNA sequence analysis using the primer 5'-GAAGATACCCACCAAAC-3', SEQ ID NO: 16, and then compared to sequences in GenBank using the BLAST algorithm. The DNA sequence in plasmid pDG869 corresponded to an open-reading-frame designated YER047C on Chromosome V. A Lambda clone encompassing this region (#6379) was obtained from the American Type Culture Collection, and a 3.2kb *Pst*I DNA fragment was isolated and ligated to *Pst*I digested pUC19 (pRK1). A 3.5kb *Bss*S1 DNA fragment was purified from pRK1, treated with DNA Pol1-Klenow, and ligated to the *Sma*I site in pUC8 (pRK16). A 3.2kb *Eco*R1 DNA fragment was isolated from pRK16 and ligated to *Eco*R1 treated pGAD424, to generate an in-frame fusion of *Irt1p* to the activation domain of Gal4 (pRK26). To generate C-terminal truncations of *Irt1p* plasmid pRK26 was treated with *Bsu*361, *Bcl*I and *Nde*I and religated to yield alleles encoding residues 1-567, 1-243 and 1-172, respectively. Measurement of β -galactosidase activity were as described in Paetkau et al., 1994.

30

Pulse-chase and immunoprecipitation

Pulse-chase analysis, protein extraction, quantitation and immunoprecipitation of HA-tagged and β -gal fusion proteins were carried out as described previously (Madura and Varshavsky, 1994). Yeast cells were labeled for 5 minutes with 35 S-Translabel (ICN Pharmaceuticals), and the reaction was terminated by the

35

addition of buffer containing cycloheximide and excess cold methionine and cysteine. Immunoprecipitations were carried out using equal cpm of lysate (that were adjusted to equal volume). Immune complexes were captured on Protein-A Sepharose and resolved on SDS-polyacrylamide gels. Autoradiographic images were quantitated by PhosphorImager analysis or densitometry. Rad23-HA was detected with HA-specific antibodies (Boehringer Manneheim, Inc.).

5

UV irradiation and survival measurement

UV irradiation (at 254nm) and estimation of survival were performed as described previously (Wilcox and Prakash 1981). Irradiated cells were allowed to recover in the dark for 3 days at 30°C.

10

Cell cycle arrest

PolIII^{ts}: Rad23-HA was expressed in a strain containing a temperature-sensitive allele of RNA polymerase II (RY262: *rpb1-1*). RY262 expressing Rad23-HA was grown at 23°C in the presence of 0.1mM CuSO₄ and then diluted 4-fold into YPD (+ 0.1mM CuSO₄) that was equilibrated at 37°C, and incubated with vigorous aeration for 2 hours. Cells were collected by centrifugation and pulse-chase measurements were performed at 37°C.

15

Growth arrest with α -factor and hydroxyurea: To measure the stability of Rad23-HA in G₁ arrested cells Rad23-HA was expressed in KMY1012, a *ura3* derivative of 4910-3-3A (Madura et al. 1990). KMY1012 was grown at 23°C to A₆₀₀ of approximately 0.3 and then suspended in YPD medium containing 10 ng/ml α -factor (Peninsula Labs). The culture was maintained at 23°C for 3 hours until greater than 95% of α -factor treated cells were unbudded and arrested in G₁. Actively growing JD47-13C cells were treated with 100 μ g/ml hydroxyurea (Sigma

20

25

30

35

Chemical Co.) until greater than 75% of the culture displayed large dumbbell shaped cells. The arrested cells were subject to pulse-chase analysis as described earlier.

5

Rad23 suppresses N-end rule toxicity

Overexpression of the N-end rule pathway causes growth inhibition which stems, at least in part, from the constitutive degradation of the essential $G\alpha$ protein (Madura and Varshavsky, 1994). The degradation of $G\alpha$ is believed to activate the mating-response pathway which causes growth arrest in G_1 . In a screen to identify high-copy suppressors of N-end rule dependent toxicity, *RAD23* was isolated. See Figure 5A. We theorized that *Rad23* might interact with the targeting components of the N-end rule pathway and thereby prevent $G\alpha$ degradation. Such an interaction would suggest that *Rad23* is a substrate of the N-end rule pathway, or a regulatory component of this proteolytic system. Two copies of the 9 residue HA epitope were linked to the C-terminus of *Rad23*. *Rad23*-HA conferred wildtype levels of UV resistance in *rad23* Δ , indicating that it is functionally competent. See Figure 5B.

The stability of *Rad23*-HA was measured by pulse-chase analysis and found to be extremely short-lived in wildtype and *ubr1* Δ cells indicating that it is not a substrate of the N-end rule pathway, contrary to our prediction. See Figure 6C. Figure 6A shows that *Rad23*-HA is unstable in *ubc4* Δ *ubc* Δ suggesting that these E2 proteins do not affect its stability. The degradation of *Rad23*-ha was also unaffected in *ubc2* Δ (Fig. 6B), a strain lacking the ubiquitin-conjugating enzyme essential for this proteolytic system. The stability of $G\alpha$ (and other substrates of the ubiquitin pathway), was unaffected in *rad23* Δ or when *Rad23* was overexpressed (data not shown), demonstrating that *Rad23*-mediated

suppression of N-end rule toxicity does not involve the mating response. Interestingly, it was discovered that *rad23* Δ also suppressed the toxic effects of N-end rule overexpression, providing genetic evidence for a connection between Rad23 and the proteolytic system (Fig. 5A).

Rad23-HA is conditionally degraded

The data demonstrate that the stability of Rad23-HA varied in a growth-stage dependent manner. The half-life of Rad23-HA exceeded 1 hour in stationary phase cells and was reduced to approximately 1-3 minutes in actively growing cells (Fig. 7A). Even when overexpressed the half-life of Rad23-HA was approximately 1 minute during active growth, attesting to the extraordinary specificity and potency of the degradation apparatus. To exclude the possibility that overall protein degradation was reduced in stationary-phase cells, thereby causing Rad23-HA stabilization, the stability of two distinct classes of substrates of the ubiquitin pathway was examined. Additionally, the *in vivo* half-life of R- β gal and Ub-P- β gal (substrates of the N-end rule and UFD pathways, respectively) were measured. See Figure 7D. Unlike Rad23-HA, R- β gal and Ub-P- β gal were efficiently degraded in both exponential and stationary-phases of growth. In contrast M- β gal, which is not recognized as a substrate of the ubiquitin pathway, remained stable in both growth conditions. These results demonstrate that the growth-stage specific degradation of Rad23-HA (and UbL^{R23}- β gal, described in Fig. 9B) is highly specific, and is not a reflection of the overall levels of proteolysis.

To further characterize the conditions that promote Rad23-HA degradation, stationary-phase yeast cells were radiolabeled to generate high levels of stable Rad23-HA.

Rad23-HA was rapidly degraded when these cells were transferred to rich (YPD) medium, and was undetectable within 15 minutes (Fig. 7B). The levels of other proteins were not affected until 60 minutes after transfer (data not shown). The rapid degradation of Rad23-HA precluded our ability to detect multi-ubiquitinated intermediates.

The C-terminal HA epitope does not contribute directly to the destabilization of Rad23-HA because other perturbations of the C-terminus also caused conditional degradation. A Rad23 mutant that lacked 29 C-terminal residues as well as the HA epitope (Rad23¹⁻³⁶⁹), displayed extreme instability in logarithmic-phase cells (Fig. 7C), resembling the degradation pattern of both Rad23-HA and UbL^{R23}- β gal (Fig. 9B). Significantly, Rad23¹⁻³⁶⁹ conferred UV resistance in *rad23 Δ* (data not shown), suggesting that the function of Rad23 in mediating protein degradation is restricted to stationary-phase cells.

20

Transient cell-cycle arrest does not affect Rad23-HA stability

The growth-stage dependent degradation of Rad23-HA prompted the examination of its stability during the cell-cycle. The growth of exponential stage cultures was arrested with α -factor (Madura and Prakash, 1990) or hydroxyurea (Sanchez et al., 1996), and Rad23-HA stability was determined. Pulse-chase studies revealed that Rad23-HA was efficiently degraded in these growth arrested cells (Fig. 8B and 8C). Also a temperature-sensitive allele of RNA Pol II was employed to asynchronously arrest growth of an actively propagating culture (Nonet et al., 1987). The data show that Rad23-HA remained extremely short-lived (Fig. 8A). We conclude from these results that the degradation of Rad23-HA is not affected by transient growth arrest of

35

exponential-phase cells.

The ubiquitin-like domain is required for Rad23-HA degradation

5 Ubiquitin is expressed either as an N-terminal fusion to specific ribosomal proteins (Finley et al., 1989), or as a chain of tandemly-linked Ub multimers (Ozkaynak et al., 1990). The C-terminus of Ub is important for its processing, activation and conjugation to cellular proteins. The C-terminal residues in most 10 ubiquitin-like domains differ from that of Ub suggesting that they are generally not excised and conjugated to other proteins.

Varshavsky and colleagues found that the expression 15 of Ub as a non-cleavable extension on β -galactosidase led to extreme instability of the fusion protein following subsequent conjugation to a multi-ubiquitin chain (Johnson et al. 1992). Since UbL^{R23} is retained in mature Rad23, its role in Rad23-HA degradation was 20 investigated by constructing a mutant that lacked this motif (Δ^{UbL} Rad23-HA). We found that Δ^{UbL} Rad23-HA was stable in actively growing cells (Fig. 9A), displaying a half-life that exceeded 10 hours during exponential growth. Significantly, Δ^{UbL} Rad23-HA failed to complement 25 the UV sensitivity of *rad23* Δ (Watkins et al. 1993), suggesting that UbL^{R23} may have a proteolytic function in DNA repair.

30 *The ubiquitin-like domain is an autonomous degradation signal*

The ability of UbL^{R23} to promote the degradation of a reporter protein was tested by linking it to β -galactosidase (UbL^{R23}- β gal). The data illustrate that UbL^{R23}- β gal is stable in stationary-phase but exceedingly 35 unstable during active growth (Fig. 9A and Fig. 9B), intensifying the degradation pattern of Rad23-HA (Fig.

7A). Long over-exposures of the autoradiograms revealed a low level of UbL^{R23}-βgal in the 0 min sample in logarithmically growing cells, and quantitative β-galactosidase activity measurements confirmed these findings (data not shown). These results demonstrate that UbL^{R23} is both necessary and sufficient for the targeting and degradation of Rad23-HA, and is predicted to contain amino acid residues that are recognized by proteolytic factors. Furthermore, UbL^{R23} contains sequences that are sensitive to regulatory signals because UbL^{R23}-βgal mimicked the regulated degradation of Rad23-HA. UbL^{R23}-βgal migrated as a set of 3 closely spaced electrophoretic bands. It is not known if these bands correspond to multiubiquitination or other modifications of UbL^{R23}-βgal.

The Ubiquitin Fusion Degradation (UFD) pathway is involved in the degradation of Rad23-HA

The placement of ubiquitin on the N-terminus of a protein such as β-galactosidase (Ub-P-βgal), can promote degradation by the Ubc4 ubiquitin-conjugating enzyme (Bachmair et al., 1986). Ubc4 assembles a multiubiquitin chain at a conserved lysine in the Ub extension of Ub-P-βgal (Johnson et al., 1992). Since the lysine residues which serve as attachment sites for the formation of a multiubiquitin chain are conserved between Ub and UbL^{R23}, we predicted that Rad23-HA might also be targeted by Ubc4. Ubc5 encodes another ubiquitin-conjugating enzyme which is approximately 90% identical to Ubc4 and is believed to have overlapping substrate specificity (Seufert and Jentsch, 1990). Rad23-HA stability was examined in *ubc4Δ ubc5Δ*. In these cells, degradation of the protein was unaffected (Fig. 6A) compared to the wildtype strain (data not shown). These findings show that this class of E2 enzymes does not target Rad23-HA for degradation.

In a search for factors that affect the degradation of Ub-P- β gal Johnson, *et al.* performed a genetic screen and identified a class of mutants (termed the UFD pathway- for ubiquitin fusion degradation pathway) that differentially affected Ub-P- β gal stability. Johnson *et al.* determined that *UFD5* was the only UFD pathway gene that was also required for the degradation of N-end rule substrates, which are distinct from Ub-P- β gal. While N-end rule substrates are ubiquitinated by Ubc2 and Ubr1, Ub-P- β gal is ubiquitinated by Ubc4. The possibility that the *ufd* mutants might affect the stability of Rad23-HA was examined. Pulse-chase measurements showed that Rad23-HA was strongly stabilized in *ufd5 Δ (Fig. 10E), but not in *ufd1-ufd4* (Figs. 10B-10D). Multiubiquitinated derivatives of Ub-P- β gal were detected in *ufd5 Δ , while Rad23-HA accumulated as an apparently unmodified protein. Although the biochemical activity of Ufd5 is unknown, these results demonstrate that the channeling of substrates to the proteasome can follow diverse routes. This observation is also supported by our finding that different proteasome mutants have distinct effects on Rad23-HA stability (see below).**

25 *Proteasome dependent degradation of Rad23-HA*

Substrates of the Ub system are generally degraded by the 26S proteasome, an evolutionarily conserved structure of $>2 \times 10^6$ Daltons. It was recently reported that a yeast pheromone-specific receptor, Ste2, is ubiquitinated but degraded in the vacuole in a proteasome-independent manner (Hicke and Riezman 1996). In contrast ornithine decarboxylase (ODC) is degraded by the 26S proteasome, although it is not ubiquitinated (Tokunaga *et al.* 1994). Given these exceptions, to the generally accepted model for targeting and degradation of ubiquitinated substrates, we measured the stability of Rad23-HA in yeast strains bearing mutations in either

proteasome subunits or vacuolar proteases, to determine if its degradation involved the ubiquitin/proteasome pathway. Cim5 is an ATPase subunit of the 19S regulatory complex of the 26S proteasome and is required for the degradation of Ub-P- β gal (Ghislain et al. 1993). The stability of Rad23-HA in exponential-stage *cim5-1* cells was measured and the results show that it was very stable ($t_{1/2}$ >10 hrs, Fig. 11B). Pre1 and Pre2 are subunits of the 20S catalytic core of the 26S proteasome, and mutants are sporulation defective and stress-sensitive. In agreement with the results observed in *cim5-1*, we found that Rad23-HA was stabilized in actively growing *pre1-1 pre2-2* cells ($t_{1/2}$ ~1 hr, Fig. 11A). In contrast the degradation Rad23-HA was unaffected in *pep4 Δ prb1- Δ 1*, which is defective in vacuolar proteolysis ((Hicke and Riezman 1996), Fig. 11E). Thus, it appears that Rad23-HA degradation requires the 26S proteasome.

The very rapid degradation of Rad23-HA precluded detection of multiubiquitin intermediates. Ubiquitinated Rad23 was previously detected (Watkins et al. 1993), suggesting that Rad23-HA degradation is ubiquitin-mediated. Mcb1 is a yeast counterpart of the human S5a protein which encodes a multiubiquitin-chain binding protein of the 26S proteasome. The stability of Rad23-HA was tested in *mcb1 Δ* and results demonstrated that it continued to be degraded rapidly (Fig. 11D). Since *mcb1 Δ* stabilizes only a subset of ubiquitinated substrates in yeast cells it is possible that other multiubiquitin-chain binding proteins can mediate Rad23-HA degradation. The stability of Rad23-HA in *doa4 Δ -1*, an isopeptidase associated with the 26S proteasome, was also measured since many substrates of the ubiquitin system are stabilized in this mutant. Surprisingly, Rad23-HA continued to be degraded in *doa4 Δ -1* (Fig. 11C). These results demonstrate that substrates of the ubiquitin system can follow diverse routes into the

proteasome.

Rad23 interacts with other components of the proteasome

Rad23 was linked to *lexA* and interacting factors
5 were sought by the 2-hybrid method (Paetkau et al.
1994). We identified *Irt1* (interaction with *Rad23*), a
protein whose C-terminal domain displays significant
homology with the 26S subunit *Yta6* (Fig. 8A, Schnall et
al. 1994) and *Cim3* and *Cim5*. See Figure 12A. The large
10 N-terminal domain of *Irt1* is not similar to any known
polypeptide sequence. The degradation of *Rad23*-HA was
unaffected in *irt1Δ* (data not shown), indicating that
the interaction between *Rad23* and *Irt1* is likely to be
of a regulatory nature.

15 To further characterize the interaction between
Rad23 and *Irt1* several deletion derivatives of *Irt1* were
constructed and tested for their ability to interact
with *Rad23* (Fig. 12B). Full-length *Irt1* (897 amino
acids) as well as three C-terminal deletion variants,
20 comprising residues 1-567, 1-243 and 1-172, were tested
in the 2-hybrid system. *Irt1*¹⁻⁵⁶⁷ lacks the highly
conserved ATPase domain located in the C-terminus, while
the larger truncations removed additional residues of
unknown function.

25

EXAMPLE III

UBIQUITIN-LIKE SEQUENCES ARE PROTEASOME INTERACTING DOMAINS

A family of proteins that contain ubiquitin-like
30 sequences (UbL's) has been identified in diverse
organisms (Garrett et al., 1995; Shen et al., 1996).
Some UbL's are post-translationally conjugated to other
proteins in a mechanism similar to that described for
ubiquitin-conjugation (Johnson et al., 1997; Mahajan et
35 al., 1997). However, a distinct class of UbL's are

retained in the original translational product and not conjugated to other proteins (Watkins et al., 1993). The proteins to which these UbL's are fused share little in common and offer no obvious clues to their biological functions. Furthermore, the effect of a UbL on the activities of the protein to which it is linked is unknown. Although UbL's display no more than 20-30% identity to the amino acid sequence of ubiquitin, their 3-dimensional structures are predicted to be highly similar (van der Spek et al., 1996). The two proteins in yeast that contain N-terminal ubiquitin-like domains were reported to be stable (Biggins et al., 1996). However, we have determined that Rad23 is ubiquitinated and degraded during the G1/S-phase transition of the cell-cycle. The fusion of ubiquitin to the N-terminus of β -galactosidase (Ub-Pro- β gal) has also been shown to cause rapid degradation by the ubiquitin pathway (Johnson et al., 1995; Bachmair et al., 1986).

Dsk2 is another yeast protein that contains a ubiquitin-like domain (UbL^{DSK}), and deletion of both genes (*rad23 dsk2*) causes a temperature sensitive growth defect (15), suggesting that their activities converge at some unknown biochemical level.

To examine if Rad23 associated with proteolytic factors we linked Rad23 and UbL^{R23} to GST and found that both GST-Rad23 and GST-UbL^{R23} formed stable interactions with the 26S proteasome. See Example I. The data presented herein demonstrate that proteasome-interaction is a feature shared by other members of the family of ubiquitin-like proteins, and indicate that UbL containing proteins mediate proteolytic functions. UbL's and UbL-containing proteins have been implicated in many biological pathways including DNA repair (Watkins et al., 1993), spindle pole-body duplication (Biggins et al., 1996), transcription elongation (Garrett et al., 1995), von Hippel Landau syndrome (Kibel et al., 1995) and nuclear/RNA transport (Mahajan

et al., 1997). The best characterized among these proteins is yeast Rad23.

The findings presented indicate that UbL/proteasome interaction is regulated. The UbL from yeast Dsk2 (UbL^{DSK}) interacts with the proteasome preferentially in actively growing cells. Overexpression of UbL^{R23} inhibits the degradation of specific substrates of the ubiquitin pathway perhaps by saturating the proteasome targeting pathway. Significantly, our results show that UbL-linked proteins interact with the proteasome without prior attachment to a multiubiquitin chain, defining a novel mechanism for targeting proteins to the proteasome.

Materials and Methods for Example III

Strains and Extracts

The yeast strains used in these studies were derived from JD47-13C; MATahis3- Δ 200trp1- Δ 63 lys2-801 ura3-52 leu2-2, 112 (J. Dohmen). Rad23 deletion (CSY85; rad23 Δ ::URA3) was made in JD47-13C using pDG28. Extracts for immunoprecipitations and affinity purified purification were described previously. (Schauber et al., 1998).

Reagents

Proteasome inhibitors were obtained from Calbiochem, glutathione-Sepharose from Pharmacia, anti-ubiquitin antibodies from Sigma, and anti- β galactosidase antibodies from Promega.

Plasmids and constructs

UBL's and CIM5 were amplified by PCR with oligonucleotides containing a 5' NcoI and 3' KpnI restriction site and ligated into similarly treated pCBGST1 (Schauber et al., 1998). The expression of the proteins was induced with 0.15 mM CuSO₄. Plasmids

encoding Pre-1-FLAG and Sen3-HA were provided by J. Dohmen and M. Hochstrasser.

UbL's are proteasome-interacting sequences. The
5 ubiquitin-like domains of yeast Rad23 and Dsk2, and
human HHR23A and -B, were linked to the C-terminus of
glutathione S-transferase (GST), and expressed in yeast.
Extracts were incubated with glutathione-Sepharose, and
bound proteins separated in a SDS-polyacrylamide gel,
10 transferred to nitrocellulose and analyzed by
immunological methods. The blot was incubated with Cim3
and Cim5 antibodies, which recognize subunits of the 26S
proteasome, and a strong interaction was detected in the
beads containing GST-UbL^{R23}. See Figure 13A, lane 2.
15 UbL^{R23}/proteasome interaction was resistant to 1M NaCl,
and treatment with detergents including 1% Triton X-100,
0.5% NP40 and 0.1% SDS (data not shown). Ubiquitin
(GST-Ub) did not interact appreciably with the 26S
proteasome (Fig. 13A, lane 3), supporting the idea that
20 ubiquitin is recognized by the proteasome only when it
is assembled into a multiubiquitin chain (Chau et al.,
1989). In contrast, the UbL may have evolved to
specifically interact with the proteasome without prior
attachment to a multiubiquitin chain. Weaker
25 interactions were detected with GST-UbL^{DSK} and GST-UbL^{HRB}
(lanes 4 and 6), but not with GST-UbL^{HRA} (lane 5). To
examine the possibility that GST-UbL^{HRA} and GST-UbL^{HRB}
might interact more favourably with human proteins we
incubated Hela cell S100 extracts with GST-UbL^{HRA} and
30 GST-UbL^{HRB}. The interacting proteins were analyzed in a
western blot with Cim5 antibodies which crossreact with
Mss1, a human counterpart of yeast Cim5 (Ghislain et
al., 1993). Mss1 was detected in GST-UbL^{HRA} and GST-
UbL^{HRB} beads (Fig. 14A, lanes 2 and 3), but not GST (lane
35 1). A control lane containing GST-UbL^{R23} interacting
proteins showed that the antibody reaction against Cim5
was efficient (Fig. 14A, lane 4). In agreement with

these findings we found that cells expressing Sen3-HA, a non-ATPase 19S subunit (DeMarini et al., 1995), also interacted with GST-UbL^{R23} but not GST (see Fig. 14A).

Consistent with these results, we detected Pre1-FLAG
5 (an epitope-tagged 20S subunit) in beads containing GST-UbL^{R23}, GST-UbL^{DSK}, and GST-UbL^{HRB} (Fig. 13B). These results show that several different subunits of the 19S and 20S components of the 26S proteasome can be detected in a complex that interacts with ubiquitin-like domains.
10 We conclude that a common biochemical property of a UbL is its interaction with catalytically active 26S proteasome.

UbL's interact with the 19S regulatory component of
15 the 26S proteasome. Based on the activities associated with UbL^{R23}, the proteasome interacting-subunit could be located in either the 19S or 20S complexes. To examine the interaction with the 19S regulatory complex GST-UbL^{HRA} and GST-UbL^{HRB} were incubated with approximately
20 5µg 19S/PA700 (a gift from Dr. G. DeMartino, Univ. of Texas, Dallas, TX), for 10 hr at 4°C. Bound proteins were resolved in SDS-PAGE and examined by silver staining. A significant fraction of the input protein was detected in the beads containing UbL^{HRA} and UbL^{HRB}
25 (Fig. 14B, lanes 2 and 3). The profile of 19S/PA700 subunits that bound GST-UbL^{HRA} and GST-UbL^{HRB} was similar demonstrating that the entire complex, rather than specific subunits, interacts with the UbL. UbL^{HRB}, but not UbL^{HRA}, showed detectable interaction with yeast
30 proteasomes, although both chimeras bound human proteasome (Fig. 14). This variance in interaction may result from subtle differences in their sequences, which might offer clues to the residues that are important for proteasome binding.

35

A novel mechanism is involved in UbL^{R23}/proteasome

interaction. Substrates of the ubiquitin system are covalently linked to a multiubiquitin chain prior to recognition by the 26S proteasome. In a search for multiubiquitin-chain binding proteins van Nocker et al., identified Mcb1, which is a component of the 19S regulatory complex of the proteasome (van Nocker et al., 1996). Since UbL's interact with the proteasome through the 19S complex (Fig. 14B), we investigated if UbL^{R23} could interact with the proteasome in *mcb1Δ*. We purified GST-UbL^{R23} from *mcb1Δ* and found that it co-precipitated Cim5 and Cim3, demonstrating that its interaction with the proteasome is not mediated by Mcb1. This result proves that there are alternate ways for substrates and regulators to interact with the proteasome, and is consistent with studies which showed that some substrates of the ubiquitin system are efficiently degraded in *mcb1Δ* (van Nocker et al., 1996).

UbL^{R23} can target heterologous proteins to the proteasome. UbL^{R23} was linked to the N-terminus of β -galactosidase (UbL^{R23}- β gal) and Ura3-HA (UbL^{R23}-Ura3-HA), and the plasmids were transformed into a yeast strain expressing GST-Cim5. Extracts were incubated with anti- β -galactosidase or anti-HA antibodies, and immunoprecipitated protein recovered on Protein-A Sepharose beads, resolved in SDS-PAGE and transferred to nitrocellulose. The nitrocellulose filter was incubated with anti-GST antibodies, and the position of full-length GST-Cim5 from a control extract, is indicated by the arrow (Fig. 15, lane 1). We found that GST-Cim5 was highly susceptible to proteolysis (as indicated by the large number of smaller fragments). Extracts containing GST-Cim5 and UbL^{R23}- β gal were incubated with anti- β -galactosidase, and a strong reaction against GST-Cim5 was detected in the immunoprecipitates (Fig. 15, lane 2). Interestingly, the degradation products of GST-Cim5 (lane 1), were not seen in lane 2 suggesting that only

intact GST-Cim5 is incorporated into the proteasome. Extracts containing only GST-Cim5 were also incubated with anti- β gal antibodies and resolved on the gel. As expected, GST-Cim5 was not precipitated in this reaction (Fig. 15, lane 3). To extend these findings further we examined if UbL^{R23}-Ura3-HA could also selectively precipitate GST-Cim5. A band consistent with GST-Cim5 was detected (lane 4), and as observed in lane 3 only intact GST-Cim5 protein was precipitated with UbL^{R23}-Ura3-HA. An extract containing only GST-Cim5 was reacted with anti-HA antibodies and GST-Cim5 was not precipitated (lane 5). We conclude that UbL^{R23} is an autonomous sequence that can target unrelated proteins to the proteasome.

15

UbL/proteasome interaction can be regulated. We found that UbL^{DSK} forms a weak association with the proteasome. The function of Dsk2 is expected to be confined to actively growing cells because it is required for spindle pole-body duplication. Our preliminary studies indicate that UbL^{DSK} interacts more favorably with the proteasome in actively growing cells. It remains to be determined how the natural C-terminal extension regulates UbL/proteasome interaction. We have reported in Example I that specific alleles of Rad23 are rapidly degraded by the ubiquitin/proteasome pathway, in a mechanism that requires UbL^{R23}. Since these Rad23 variants are degraded only in actively growing cells, it appears that UbL^{R23}/proteasome interaction may also be regulated.

30

UbL^{R23} interferes with proteasome function. The high affinity interaction between UbL^{R23} and the 26S proteasome suggested that it might affect the degradation of substrates of the ubiquitin system. We examined the stability of substrates of the N-end rule

35

(Arg- β gal and Leu- β gal) and UFD pathways (Ub-Pro- β gal), by measuring β -galactosidase activity of test substrates. The levels of Leu- β gal and Ub-Pro- β gal were 2-3 fold higher in cells expressing GST-UbL^{R23}, than in the GST control. In contrast, the activity in cells expressing Met- β gal and Arg- β gal was unchanged (data not shown). To confirm these results we measured the *in vivo* half-lives of test substrates by pulse-chase analysis. We found that Leu- β gal and Ub-Pro- β gal were moderately stabilized in cells expressing GST-UbL^{R23} (Fig. 16B), as compared to GST (Fig. 16A). These results are in agreement with the β -galactosidase activity measurements. Significantly, ubiquitinated derivatives of Leu- β gal and Ub-Pro- β gal accumulated in cells expressing GST-UbL^{R23}, indicating that UbL^{R23} interferes with a post-targeting step in substrate degradation. This effect is most easily seen in Leu- β gal levels at the 0 time-point. These results suggest that UbL^{R23} interaction with the proteasome can block, or otherwise interfere with, the access of specific substrates to the proteasome. The alternate possibility that GST-UbL^{R23} increased ubiquitin-conjugation is considered less likely because the rate of Leu- β gal degradation was reduced, and not increased as would be expected if it was more efficiently targeted. In contrast to the stabilization of Leu- β gal, Arg- β gal remained extremely unstable in strains expressing either GST or GST-UbL^{R23}. This result suggests that the fate of Type I (Arg- β gal) and Type II (Leu- β gal) substrates of the N-end rule pathway may diverge following their conjugation to ubiquitin by the targeting components Ubr1/Ubc2).

The function of ubiquitin-like domains (UbL) was previously unknown. We report here that the UbL is a cis-acting signal that can translocate UbL-linked proteins to the proteasome. In addition to the Rad23 proteins and Dsk2, we also examined the interaction

between Elongin-B and the proteasome. Consistent with the findings shown in Fig. 13, we detected an interaction with Cim5 (data not shown). Elongin B is a UbL-containing protein that forms a heterotrimeric complex which modulates transcription by RNA Pol II. We have also reported elsewhere that UbL^{R23} can function as a portable degradation signal, when fused to the N-terminus of β -galactosidase (UbL^{R23}- β gal). Although the biological significance of UbL/proteasome interaction is unknown, we suggest that UbL's can be either substrates or regulators of the proteasome. There also exists an interesting possibility that a UbL-linked protein can promote the degradation of other proteins in trans, by binding and transporting them to the proteasome. A particular advantage of this mechanism for proteasome targeting is that an elaborate ubiquitin-dependent apparatus is dispensed with, and the in vivo levels of a substrate could be regulated by the concentration of its cognate UbL-containing partner, and its affinity for the proteasome. A precedent for this mechanism is noted by the (ubiquitin-independent) antizyme-mediated degradation of ornithine decarboxylase by the proteasome (Murakami, et al., 1992). A potential target for Rad23-mediated degradation could be Rad4, to which it binds with high affinity. Rad23 and Rad4 are both important for the assembly of the nucleotide excision repair complex, and genetic and biochemical studies have implicated a regulatory role for Rad23. We have shown that Rad23 and Rad4 can be purified in a complex with the proteasome, although it remains to be determined if Rad23 influences Rad4 stability. The Rad23-mediated link between DNA repair and protein degradation may define a mechanism to recycle the repair complex, or to facilitate recovery after the completion of DNA repair.

Of the four UbL's present in yeast, only Smt3 and Rub1 are conjugated post-translationally to other

proteins. A mammalian counterpart of Smt3 (SUMO) is covalently linked to RanGAP1, although this modification does not appear to promote degradation. However, it is possible that only a small fraction of RanGAP1 is post-translationally modified, and its SUMO-mediated turnover may be masked by the large fraction of unmodified RanGAP1. We showed in Fig. 13 that mono-ubiquitin (GST-Ub) failed to interact with the proteasome. Since ubiquitin interacts with the proteasome only when it is assembled into a multiubiquitin chain, we propose that substrate-linked Smt3 and substrate-linked Rub1 might also be targeted to the proteasome. This idea can be tested once the physiological targets of Smt3 and Rub1 are identified.

UbL-containing proteins may prevent the degradation of other proteins by blocking their access to proteolytic factors. For instance, GST-UbL^{R23} interaction with the proteasome inhibited the degradation of specific substrates of the ubiquitin pathway (Fig. 16). We found that UbL^{R23} stabilized Leu-βgal but not Arg-βgal, which are distinct substrates of the N-end rule pathway.

UbL^{R23} also stabilized Ub-Pro-βgal, a substrate of the UFD pathway. Pulse-chase experiments suggested that inhibition of degradation occurred at a post-targeting step because multi-ubiquitinated derivatives of Leu-βgal and Ub-Pro-βgal accumulated in the presence of GST-UbL^{R23}.

Rad23 and Dsk2 are the only yeast proteins that retain ubiquitin-like domains in the mature proteins. Rad23 is required for nucleotide excision repair, while Dsk2 is involved in spindle pole-body (SPB) duplication. Deletion of both genes (rad23 dsk2) causes a temperature sensitive growth defect indicating that the biochemical activities of Rad23 and Dsk2 intersect, possibly at the level of the 26S proteasome. UbL^{R23}, but not UbL^{DSK},

interferes with the degradation of specific test proteins. We suggest that substrates of the N-end rule and UFD pathway may be channeled to a specific proteasome isoform that is recognized only by UbL^{R23}.
5 Interestingly, UbL^{DSK}/proteasome interaction is enhanced in actively growing cells, also suggesting that compositionally distinct types of proteasomes may regulate UbL interactors. This observation is consistent with a previous study which showed that
10 specific 20S proteasome subunits are replaced following γ -interferon treatment in mammalian cells (Gaczynska, et al., 1993).

15

EXAMPLE IV**ENHANCED THERMOSTABILITY OF RAD23 AND USE OF THE UBL^{R23} DOMAIN TO CONFER THERMOSTABILITY ON FUSION PROTEINS**

Rad23 was purified to homogeneity from bacteria and
20 subjected to structural analysis by circular dichroism (CD-spectra). The analysis was done along with other proteins unrelated to this work. The CD-spectra revealed that Rad23 is a typical globular protein, which is highly soluble and contains substantial α -helical
25 character. See Figure 17. However, when the thermal stability of the protein was analyzed the data revealed that it did not display the cooperative melting profile typically observed for globular proteins. See Figure 18. Indeed a melting transition was not detected even
30 when Rad23 was heated to excess of 90°C. Consistent with this result when the protein sample was returned to 23°C it continued to display CD-spectra consistent with a well-folded globular and soluble protein. In
35 contrast, other proteins that were analyzed at the same time displayed the expected cooperative denaturation at 52°C indicating that the experimental conditions and the

function of the instrument were normal.

The results obtained indicate that the UbL is a
cis-acting, temperature stabilizer. As described in the
previous examples, UbL^{R23} has been fused to β -
5 galactosidase. Like Rad23, this fusion protein can be
heated without loss of secondary structure.
Additionally, exposure to high temperatures did not
inactivate the enzymatic portion of the fusion protein.

This observation indicates that the UbL has broad
10 applications in the generation of fusion proteins having
enhanced thermostability.

REFERENCES

15 Lam, Y.A., Xu, W., DeMartino, G.N. & Cohen, R.E. *Nature*
385, 737-740 (1997).

20 Coux, O., Tanaka, K. & Goldberg, A.L. *Annu. Rev.*
Biochem. **65**, 801-847 (1996).

Masutani, C., et al. *EMBO J.* **13**, 1831-1843 (1994).
Rubin, D.M., et al. *Nature* **370**, 655-657 (1996).

25 Ausubel, F.M. (1992) *Current Protocols in Molecular*
Biology. Wiley-Interscience, New York.

30 Bachmair, A., Finley, D. and Varshavsky, A. 1986. *In*
vivo half-life of a protein is a function of its amino-
terminal residue. *Science* **234**: 179-186.

35 Biggins, S., Ivanovska, I. and Rose, R.D. 1996. Yeast
ubiquitin-like genes are involved in duplication of the
microtubule organizing center. *J. Cell Biol.* **133**: 1331-
1346.

40 Boeke, J.D., Lacroute, F. and Fink, G.R. 1984. A
positive selection for mutants lacking orotidine-5'-
phosphate decarboxylase activity in yeast: 5-fluoro-
orotic acid resistance. *Mol. Gen. Genet.* **197**: 345-346.

Bootsma, D. and Hoeijmakers, J.H. 1993. DNA repair.
Engagement with transcription. *Nature* **363**: 220-223.

- Chen, P., Johnson, P., Sommer, T., Jentsch, S. and
Hochstrasser, M. 1993. Multiple ubiquitin-conjugating
enzymes participate in the in vivo degradation of the
5 yeast MAT α 2 repressor. *Cell* **74**: 357-369.
- Finley, D., Bartel, B. and Varshavsky, A. 1989. The
tails of ubiquitin precursors are ribosomal proteins
whose fusion to ubiquitin facilitates ribosome
10 biogenesis. *Nature* **338**: 394-401.
- Friedberg, E.C., Walker, G.C. and Siede, W. (1995) *DNA
Repair and Mutagenesis*. American Society for
Microbiology, Washington, D. C.
- 15 Ghislain, M., Udvardy, A. and Mann, C. 1993. S.
cerevisiae 26S protease mutants arrest cell division in
G2/metaphase. *Nature* **366**: 358-361.
- 20 Gietz, D., St. John, A., Woods, R.A. and Schiestl, R.H.
1992. Improved method for high efficiency transformation
of intact yeast cells. *Nuc. Acids Res.* **20**: 1425-1434.
- Guthrie, C. and Fink, G.R. (1991) *Guide to Yeast
Genetics and Molecular Biology*. Academy Press, New York.
- 25 Guzder, S.M., Bailly, V., Sung, P., Prakash, L. and
Prakash, S. 1995a. Yeast DNA repair protein RAD23
promotes complex formation between transcription factor
TFIIH and DNA damage recognition factor RAD14. *J. Biol.
30 Chem.* **270**: 8385-8388.
- Guzder, S.N., Habraken, Y., Sung, P., Prakash, L. and
Prakash, S. 1995b. Reconstitution of yeast nucleotide
excision repair with purified Rad proteins, Replication
35 Protein A, and transcription factor TFIIH. *J. Biol.
Chem.* **270**: 12973-12976.
- Hershko, A. 1991. The ubiquitin pathway for protein
degradation. *Trends in Biochem. Sci.* **16**: 265-268.
- 40 Hicke, L. and Riezman, H. 1996. Ubiquitination of a
yeast plasma membrane receptor signals its ligand-
stimulated endocytosis. *Cell* **84**: 277-287.
- 45 Johnson, E.S., Bartel, B., Seufert, W. and Varshavsky,
A. 1992. Ubiquitin as a degradation signal. *EMBO J.* **11**:
497-505.
- 50 Johnson, E.S., Ma, P.C.M., Ota, I.M. and Varshavsky, A.
1995. A proteolytic pathway that recognizes ubiquitin as

- a degradation signal. *J. Biol. Chem.* **270**: 17442-17456.
- Liu, H., Krized, J. and Bretscher, A. 1992.
5 Construction of a *GAL1*-regulated yeast cDNA expression library and its application to the identification of genes whose overexpression causes lethality in yeast. *Genetics* **132**: 665-673.
- Madura, K. and Prakash, S. 1990. Transcript levels of
10 the *Saccharomyces cerevisiae* DNA repair gene *RAD23* increases in response to UV light and in meiosis but remain constant in the mitotic cell cycle. *Nuc. Acids Res.* **18**: 4737-4742.
- Madura, K., Prakash, S. and Prakash, L. 1990.
15 Expression of the *Saccharomyces cerevisiae* DNA repair gene *RAD6* that encodes a ubiquitin conjugating enzyme, increases in response to DNA damage and in meiosis but remains constant during mitotic cell cycle. *Nuc. Acids Res.* **18**: 771-778.
20
- Madura, K. and Varshavsky, A. 1994. Degradation of $G\alpha$
by the N-end rule pathway. *Science* **265**: 1454-1458.
- Nonet, M., Scafe, C., Sexton, J. and Young, R. 1987.
25 Eukaryotic RNA polymerase conditional mutant that rapidly ceases mRNA synthesis. *Mol. Cell. Biol.* **7**: 1602-1613.
- Ozkaynak, E., Finley, D., Solomon, M.J. and Varshavsky, A. 1990. The yeast ubiquitin genes: A family of
30 natural gene fusions. *EMBO J.* **6**: 1429-1439.
- Paetkau, D.W., Riese, J.A., MacMorran, W.S., Woods, R.A. and Gietz, R.D. 1994. Interaction of the yeast *RAD7* and
35 *SIR3* proteins: implications for DNA repair and chromatin structure. *Genes & Dev.* **8**: 2035-2045.
- Prakash, S., Sung, P. and Prakash, L. 1993. DNA repair genes and proteins of *Saccharomyces cerevisiae*. *Annu. Rev. Genet.* **27**: 33-70.
40
- Rothstein, R. 1991. Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast. *Methods Enzymol.* **194**: 281-301.
45
- Sancar, A. 1996. DNA Excision Repair. *Annu. Rev. Biochem.* **65**: 43-81.
- Sanchez, Y., Desany, B.A., Jones, W.J., Liu, Q., Wang, B. and Elledge, S.J. 1996. Regulation of *RAD53* by the
50

- ATM-like kinases *MEC1* and *TEL1* in yeast cell cycle check point pathways. *Science* **271**: 357-360.
- 5 Scheffner, M., Nuber, U. and Huibregtse, J.M. 1995. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. *Nature* **373**: 81-81=3.
- 10 Schiestl, R.H. and Prakash, S. 1989. Interactions of the *RAD7* and *RAD23* excision repair genes of *Saccharomyces cerevisiae* with DNA repair genes in different epistasis groups. *Curr. Genet.* **16**: 219-223.
- 15 Seufert, W. and Jentsch, S. 1990. Ubiquitin-conjugating enzymes *UBC4* and *UBC5* mediate selective degradation of short-lived and abnormal proteins. *EMBO J.* **9**: 543-550.
- 20 Sweder, K.S. and Hanawalt, P.C. 1992. Preferential repair of cyclobutane pyrimidine dimers in the transcribed strand of a gene in yeast chromosomes and plasmids is dependent on transcription. *Proc. Natl. Acad. Sci. USA* **89**: 10696-10700.
- 25 Tokunaga, F., Goto, T., Koide, T., Murakami, Y., Hayashi, S.-I., Tamura, T., Tanaka, K. and Ichihara, A. 1994. ATP- and antizyme-dependent endoproteolysis of ornithine decarboxylase to oligopeptides by the 26S proteasome. *J. Biol. Chem.* **269**: 17382-17385.
- 30 Toniolo et al. 1988. *Proc. Natl. Acad. Sci.* **85**:851-855.
- 35 van der Spek, P.J., Eker, A., Rademakers, S., Visser, C., Sugasawa, K., Masutani, C., Hanaoka, F., Bootsma, D. and Hoeijmakers, J.H.J. 1996. XPC and human homologs of *RAD23*: intracellular localization and relationship to other nucleotide excision repair complexes. *Nuc. Acids Res.* **24**: 2551-2559.
- 40 Varshavsky, A. 1992. The N-end rule. *Cell* **69**: 725-735. Watkins, J.F., Sung, P., Prakash, L. and Prakash, S. 1993. The *Saccharomyces cerevisiae* DNA repair gene *RAD23* encodes a nuclear protein containing a ubiquitin-like domain required for biological function. *Mol. Cell Biol.* **13**: 7757-7765.
- 45 Wiborg et al. 1985. *EMBO J.* **4**:755-759.
- 50 Wilcox, D.R. and Prakash, L. 1981. Incision and postincision steps of pyrimidine dimer removal in excision-defective mutants of *Saccharomyces cerevisiae*. *J. Bacteriol.* **148**: 618-623.

- Ciechanover, A. (1994) *Cell* **79**, 13-21.
- Hochstrasser, M. (1996) *Annu. Rev. Genet.* **30**, 405-439.
- 5 Varshavsky, A. (1997) *Trends Biochem. Sci.* **22**, 383-387.
- Pickart, C. M. (1997) *FASEB J.* **11**, 1055-1066.
- Hicke, L. & Riezman, H. (1996) *Cell* **84**, 277-287.
- 10 Murakami, Y., Matsufuji, S., Kameji, T., Hayashi, S, Igarashi, K., Tamura, T., Tanaka, K. and Ichihara, A. (1992) *Nature* **360**, 597-599.
- 15 Garrett, K. P., Aso, T., Bradsher, J. N., Foundling, S. I., Lane, W. S., Conaway, R. C. & Conaway, J. W. (1995) *Proc. Natl. Acad. Sci. USA.* **92**, 7172-7176.
- 20 Shen, Z., Pardington-Purtymun, P. E., Comeaus, J. C., Moyzis, R. K. and Chen, D. J. (1996) *Genomics* **36**, 271-279.
- Johnson, E. S. a. B., G. (1997) *J. Biol. Chem.* **272**, 26799-26802.
- 25 Mahajan, R., Delphin, C., Guan, T., Gerace, L. and Melchior, F. (1997) *Cell* **88**, 97-107.
- 30 Watkins, J. F., Sung, P., Prakash, L. & Prakash, S. (1993) *Mol. Cell. Biol.* **13**, 7757-7765.
- van der Spek, P. J., Visser, C. C., Hanaoka, F., Smit, B., Hagemeijer, A., Bootsma, D. & Hoeijmakers, J. H. J. (1996) *Genomics* **31**, 20-27.
- 35 Johnson, E. S., Ma, P. C. M., Ota, I. M. & Varshavsky, A. (1995) *J. Biol. Chem.* **270**, 17442-17456.
- 40 Bachmair, A., Finley, D. & Varshavsky, A. (1986) *Science* **234**, 179-186.
- Biggins, S., Ivanovska, I. & Rose, R. D. (1996) *J. Cell Biol.* **133**, 1331-1346.
- 45 Schaubert, C., Potts, W., Kirkpatrick, R. D., Gietz, R. D., Chen, L. and Madura, K. *Submitted* .

- Guzder, S. N., Sung, P., Prakash, L and Prakash, S. (1996.) *J. Biol. Chem.* **271.**, 8903-8910.
- 5 Madura, K. & Varshavsky, A. (1994) *Science* **265**, 1454-1458.
- Varshavsky, A. (1992) *Cell* **69**, 725-735.
- 10 Schaubert, C., Chen, L., Tongaonkar, P., Vega, I., Lambertson, D., Potts, W. and Madura, K. (1998) *Nature (in press)*.
- Kibel, A., Iliopoulos, O., DeCaprio, J. & Kaelin, W. (1995) *Science* **269**, 1444-1446.
- 15 Coux, O., Tanaka, K. & Goldberg, A. L. (1996) *Annu. Rev. Biochem.* **65**, 801-847.
- 20 Chau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker, D., Gonda, D. K. & Varshavsky, A. (1989) *Science* **243**, 1576-1583.
- Ghislain, M., Udvardy, A. & Mann, C. (1993) *Nature* **366**, 358-361.
- 25 DeMarini, D. J., Papa, F. R., Swaminathan, S., Ursic, D., Rasmussen, T. P., Culbertson, M. R. & Hochstrasser, M. (1995) *Mol. Cell. Biol.* **15**.
- 30 Merrick, W. C. (1979) *Meth. Enzymol.* **60**, 108-123.
- Heinemeyer, W., Kleinschmidt, J. A., Saidowsky, J., Escher, C. & Wolf, D. H. (1991) *EMBO J.* **10**, 555-562.
- 35 Masutani, C., Sugasawa, K., Yanagisawa, J., Sonoyama, T., Ui, M., Enomoto, T., Takio, K., Tanaka, K., van der Spek, P. J., Bootsma, P. J., Hoeijmakers, J. H. J. & Hanaoka, F. (1994) *EMBO J.* **13**, 1831-1843.
- 40 van Nocker, S., Sadis, S., Rubin, D. M., Glickman, M., Fu, H., Coux, O., Wefes, I., Finley, D. & Vierstra, R. D. (1996) *Mol. Cell. Biol.* **16**, 6020-6028.
- 45 Murakami, Y., Tanaka, D., Matsufuji, Y. and Hayashi, S. (1992) *Biochem. J.* **283**, 661-664.
- Guzder, S. N., Habraken, Y., Sung, P., Prakash, L. & Prakash, S. (1995) *J. Biol. Chem.* **270**, 12973-12976.

Wang, Z., Wei, S., Reed, S. H., Wu, X., Svejstrup, J. Q., Feaver, W. J., Kornberg, R. D. and Friedberg, E. C. (1997) *Mol. Cell. Biol.* **17**, 635-643.

5 Miller, R. D., Prakash, L. & Prakash, S. (1982) *Mol. Gen. Genet.* **188**, 235-239.

Gaczynska, M., Rock, K. L. & Goldberg, A. L. (1993) *Nature* **365**, 264-267.

10

While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims.

20

What is claimed is:

1. A method for rapid and efficient purification of proteasomes from cells comprising:

- 5 a) immobilizing an amino acid sequence having a UbL domain to a solid support;
- b) exposing said immobilized UbL domain to a cell lysate;
- c) eluting non-specifically bound proteins; and
- 10 d) eluting said proteasome from said solid support, thereby purifying said proteasome from said cell lysate.

2. A method as claimed in claim 1, wherein said UbL domain has the amino acid sequence selected

15 from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO: 11, and SEQ ID NO: 12.

20 3. A method as claimed in claim 1, wherein said UbL domain and said cell lysate are isolated from the same species.

25 4. A kit for the rapid purification of proteasomes from a cell lysate, said kit containing: a UbL domain affixed to a solid support, one or more containers, a wash solution and an elution buffer.

30 5. A kit as claimed in claim 4, further comprising a solution useful in performing a purification method of the invention, selected from the group consisting of saline, buffer, diluent, and frozen cell extract.

6. A DNA construct encoding a fusion protein for assessing the proliferative potential of malignant cells comprising:

5 a) a first nucleic acid sequence encoding a promoter element; and

b) a second nucleic acid sequence encoding a UbL domain operably linked to a third nucleic acid sequence encoding a reporter gene, expression of said UbL domain and said reporter gene being regulated by
10 said promoter.

7. A DNA construct as claimed in claim 6, said
15 construct being inserted into a vector.

8. A DNA construct according to claim 6, wherein said second nucleic acid encodes a UbL domain having an amino acid sequence selected from the group
20 consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO: 11, and SEQ ID NO: 12.

9. A DNA construct according to claim 6,
25 wherein said reporter gene is selected from the group of genes consisting of β galactosidase, URA3, luciferase, mammalian chloramphenicol transacetylase (CAT) gene, and green fluorescent protein (GFP) gene.

30 10. A method for assessing the proliferative potential of malignant cells, comprising:

a) introducing into a target cell a DNA construct encoding a fusion protein, said fusion protein comprising a UbL domain operably linked to a reporter

molecule; and

5 b) assessing the half-life of said fusion gene, a short half-life being indicative of a rapidly growing cell and a longer half-life being indicative of a quiescent cell.

10 11. A method as claimed in claim 10 wherein said UbL domain has an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO: 11, and SEQ ID NO: 12.

15 12. A method as claimed in claim 10, wherein said reporter gene is selected from the group of genes consisting of β galactosidase, URA3, luciferase, mammalian chloramphenicol transacetylase (CAT) gene, and green fluorescent protein (GFP) gene. consisting of

20 13. A DNA construct encoding a thermostable fusion protein, comprising a first nucleic acid sequence encoding a UbL domain operably linked to a second nucleic acid sequence encoding a protein of interest.

25 14. A DNA construct as claimed in claim 11, wherein said first nucleic acid sequence encodes a UbL domain having an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO: 11, and SEQ ID NO: 12.

30

35 15. A DNA construct as claimed in claim 11, wherein said second nucleic acid molecule encodes a polymerase enzyme.

16. A DNA construct encoding a fusion protein for selecting for drug resistance in malignant cells comprising:

5 a) a first nucleic acid sequence encoding a promoter element; and

b) a second nucleic acid sequence encoding a UbL domain operably linked to a third nucleic acid sequence encoding a selectable marker gene, expression of said UbL domain and said selectable marker gene being
10 regulated by said promoter.

17. A DNA construct as claimed in claim 16, wherein said second nucleic acid gene encodes a UbL domain having a sequence selected from the group
15 consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO: 11, and SEQ ID NO: 12.

18. A DNA construct as claimed in claim 16, wherein said selectable marker gene is selected from the
20 group consisting of the neomycin gene, or antibiotic resistance genes.

Fig. 1A






Fig. 1B









Figure 2

4/20






Figure 4

6/20

Fig. 5A





Fig. 5B






Fig. 7A




Fig. 7B




Fig. 7C






Fig. 7D



9/20



10/20

Fig. 9A









Fig. 9B



11/20



12/20



IRT1 602 VMDDIAGLES AKYSLKEAVVYFFLRPDLFRGL . REPV RGM L L F G P P G T G K T M L A R A V A
 YTA6 172 VYMED IAGLRNAKNSLKEAVVYFFLRPDLFKGL . REPV RGM L L F G P P G T G K T M L A K A V A
 CIM3 206 VTVSDVGGCKDQIEKLRREVVELP L L S P E R F A T L G I D P P K G I L L Y G P P G T G K T L C A R A V A
 CIM5 145 STYD MWGGLTKQIKEIKEVIELPVKHPELESGLAQP KGVILY G P P G T G K T L L A R A V A

IRT1 660 TESHS T F S I S A S S L T S K Y L G E S E K L V R A L F A I A K K L S P S I I F V D E I D S I M G S R N N E N E
 YTA6 230 TESNS T F S V S A S S L L S K Y L G E S E K L V R A L F Y M A K K L S P S I I F I D E I D S M L T A R . S D N E
 CIM3 265 NRJDA T F I R V I G S E L V C K Y V G E G A R M V R E L F E M A R T K K A C I I F F D E I D A V G G A R F D D G A
 CIM5 204 HHTDCKFIRVSGAELVCKYI G E G S R M V R E L F V M A R E F A P S I I F M D E I D S I G S T R V E G S G

IRT1 719 NESS . . RRIKNEFLVQSSLS S A A A G S N K S N T N N S D T N G D E D D T R V L V L A A T N L P W S I D
 YTA6 288 NESS . . RRIKTELLQWSSLS S A T A O S E D R N N T L D S R V L V L G A T N L P W A I D
 CIM3 324 GGDNEVQRTM L E L I T H Q L D G F D P R G N I K V M F A T N R P N T H L D
 CIM5 263 GGDSEVQRTM L E L L N Q L D G F E T S K N I K L I M A T N R L D I L D

IRT1 776 EAARR . . R F V R R O Y I P L P E D O T R H V Q F K K I L I S H O K H L T E S D F D E L V K I T E G Y S G S D I T
 YTA6 337 DAARR . . R F S R K L Y I P L P D Y E T R L Y E L K R L M A K O K N S L O D L D Y E L I T E M T E G F S G S D L T
 CIM3 363 PALLRPGRI DRKVEFSLPDLEGR . A N I F R I H S K S M S V E R G I R W E L I S R L C P N S T G A E I R
 CIM5 302 PALLRPGRI DRKIEFP P P S V A A R . A E I I R I H S R K W N L T R G I N L R K V A E K M N G C C S G A D V K

IRT1 833 SLAKDAAMGPT R D L G D K I
 YTA6 394 SLAKEAAMEP I R D L G D K I
 CIM3 421 SVCTEAGMFA I R A R R K V A
 CIM5 360 GVCTEAGMYA I R R R I H V

Fig. 12A




Fig. 12B

Fig. 13A




Fig. 13B




Fig. 14A





Fig. 14B PA700 (19S)







Figure 15






Figure 17




Figure 18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/12846**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :C07K 1/22, 14/00, 17/00; C12N 15/09; C12Q 1/00

US CL :435/4, 317.1, 320.1; 536/350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/4, 317.1, 320.1; 536/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog

terms: ubiquitin, proteosome, protease, Rad23, fusion protein

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	VAN NOCKER et al "Arabidopsis MBP1 gene encodes a conserved ubiquitin recognition component of the 26S proteosome" Proc Natl Acad Sci USA, 23 January 1996, vol 93, no 2, pages 856-860.	1, 3-5
Y	PETERS et al. "Ultrastructure of the approximately 26S complex containing the approximately 20S cylinder particle" Eur J Cell Biol., 1 December 1991, vol 56, no 2, pages 422-432	1, 3-5
Y	DEVERAUX et al. "A 26S protease subunit that binds ubiquitin conjugates" Journal of Biological Chemistry, 11 March 1994, vol 269, no 10, pages 7059-7061	1, 3-5

 Further documents are listed in the continuation of Box C.
 See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

30 AUGUST 1998

Date of mailing of the international search report

28 SEP 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRADLEY S. MAYHEW

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/12846

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 5,132,213 (BACHMAIR et al) 21 June 1992, fig. 3a and column 9, lines 8-18.	6, 7, 9, 13, 16 and 18 ----- 10 and 12
Y	GLOTZER et al. "Cyclin is degraded by the ubiquitin pathway" Nature, 10 January 1991, vol 349, pages 132-138	10 and 12

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/12846**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 2, 8, 11, 14 and 17
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claims 2, 8, 11, 14 and 17 are drawn to polypeptides or polynucleotides having specific sequences. However, a sequence listing in a computer readable format has not been submitted with the application. Therefore, these claims are unsearchable.
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.